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In the treatment of heart patients, as a bridge to recovery, the challenge currently in using 
a continuous flow left ventricular assist device (LVAD), is to provide a method to monitor the 
recovery of the heart. This dissertation addresses the hypothesis that continuous monitoring of the 
ejection fraction of a patient implanted with an LVAD should be to examine the progress of the 
patient without the need for excessive in vivo measurements. Also, the ejection fraction can be 
used to provide a control mechanism for the pump depending on the requirements of each patient. 
In this dissertation, the left ventricle, in the presence of the LVAD was studied using hemodynamic 
data obtained from a well established computer simulation model of the left ventricle 
supplemented with a generic pump.  
It is evident from the model that the presence of the pump alters the dynamics of the left 
ventricular volume curve because of the changes in the dynamics of the aortic valve. As a result, 
there rises the necessity to define ejection fraction in the presence of an LVAD. Interestingly, a 
sharing of blood between the ventricle and the pump was observed irrespective of the input of the 
pump, up until the point where the aortic valve permanently shuts down.  
An appropriate definition of ejection fraction in the presence of an LVAD is the ratio of 
the volume of blood ejected from the ventricle through the aortic valve to the amount of blood 
available in the ventricle just before ejection begins. The simulations in this study proved that 
ejection fraction defined as stated, removing the effects created by the pump. This provides 
necessary information to monitor the recovery of the heart, and also information about sharing of 
blood, which helps understand the cost of providing a feedback control mechanism to control the 
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CHAPTER 1  
INTRODUCTION 
Transportation of vital nutrients forms the basis for life. The mode of transportation of the 
required nutrients varies depending on the type of organism. A human is a multi-cellular organism 
with multiple layers of complexity, demanding a large number of nutrients to maintain 
functionality and to stay alive. 
Transport of these nutrients happens through the blood, a viscous fluid, which traverses 
through a very robust network of vessels known as the circulatory system. Keeping a good flow 
of blood in the circulatory system is vital to maintaining a perfect physiological balance in the 
human body.  
The circulatory system consists of a closed – loop network of blood vessels which facilitate 
a one – way flow of blood that helps carry oxygen-rich blood from the lungs to various tissues of 
the body, and in return, removes the resulting carbon dioxide from the tissues through the lungs 
[1]. Regulation of blood flow is critical,and requires a pump to do the same to counter various 
forces that the body encounters on a typical day. This pump is the heart. The heart combined with 
the circulatory system forms the cardiovascular system [1].  
1.1 Heart and The Cardiovascular System 
The heart plays a central role in delivering blood to the various parts of the body. It is a 
muscular organ which pumps blood through the circulatory system [2]. Blood supplies nutrients 
and oxygen to various organs, tissues and cells; and aids in the removal of the metabolic wastes 
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and carbon dioxide from these organs [3]. Figure 1.1 shows a representative diagram of a human 
heart.  
 
Figure 1.1: Diagram of the human heart 
(https://en.wikipedia.org/wiki/Heart#/media/File:Diagram_of_the_human_heart_(cropped).svg,Permission to use in 
Appendix F) 
 
The human heart is divided into two main halves, the left heart and the right heart, based 
on the vertical plane from one’s perspective. Right heart receives deoxygenated blood from the 
rest of the body and sends it through the pulmonary circulatory system to the lungs, which then 
removes carbon-dioxide and replenishes it with oxygen. From the lungs, oxygenated blood enters 
the left heart which then supplies blood to the rest of the body [2].  
Each side of the human heart is made up of two chambers, the atrium and the ventricle. 
The atrium is where the blood from the blood vessels throughout the body enters the heart,and the 
ejection of blood into the circulatory system is from the chamber known as the ventricle. The flow 
of blood from the atrium into the ventricle and from the ventricle into the rest of the circulatory 
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system is regulated by a set of valves. For the purposes of this dissertation, the valves that are of 
interest are the bicuspid or mitral valve and the aortic valve.  
Blood passes through various parts of the body through the circulatory system using a vast 
system of channels known as blood vessels. Two main distribution networks are used to 
characterize the blood vessels, (i) systemic circulation and (ii) the pulmonary circulation [1, 2]. 
The circulatory system is a closed-loopsystem that starts and ends at heart. Figure 1.2 shows the 
entire circulatory system in the human body. The blood vessels shown in red represent the vessels 
which carry oxygenated blood and the ones in blue represent the deoxygenated blood.  
There are three different groups of blood vessels, (i) Arteries, vessels which carry blood 
away from the heart, (ii) Capillaries, tiny vessels that facilitate the exchange of material between 
the blood and the tissue cells and finally, (iii) Veins: Vessels which carry blood back to the heart. 
 
Figure 1.2: the Human Circulatory System 




1.2 Heart Failure 
As with any mechanical system, the cardiovascular system is subject to fail under certain 
conditions. A chronic, progressive condition in which the heart muscle is no longer able to pump 
sufficient blood that meets the human body’s requirements of oxygen and nutrients, results in a 
condition known as heart failure[4]. This can be caused either by the inability of the heart to fill in 
enough blood or to produce enough force to pump blood to the rest of the body or due to both 
reasons[4, 5]. Millions of people are affected by heart failure across the world and is one of the 
primary reasons for fatalities in the United States according to the American Heart Association 
(AHA) [6]. 
Quoting from MedlinePlus, a service of the National Library of Medicine, “Heart failure 
does not mean that the heart has stopped to work or is about to stop working” [7]. Over time, heart 
failure develops due to the weakening of the heart’s pumping action. It is a chronic condition that 
can require escalating medical care over time.  
The main difficulties with detecting heart failure at an early stage are the compensating 
mechanisms in the human body that cope up for the loss of blood. These compensatory 
mechanisms include, the heart pumping faster, developing more muscle mass to pump stronger, 
blood vessels narrowing to raise the blood pressure, and diverting blood from less vital tissues to 
more important ones[4]. Eventually, symptoms which are detectable include exercise intolerance 
and fatigue, among others.  
Diseases such as coronary heart diseases, high blood pressure, and diabetes are common 
causes of heart failure[5]. Other factors such as smoking, obesity, food habits, and physical 
inactivity also contribute to heart failure.  
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1.2.1 Types of Heart Failure 
Heart failure can be single ventricle, either right or left, or biventricular [8]. The different 
types of heart failures are discussed in [4, 5]. The left ventricle is the largest of the chambers in 
the heart, as it needs to develop enough pumping power to overcome systemic vascular resistance. 
The left-sided or Left ventricular failure means the left side of the heart is having difficulty 
maintaining adequate blood flow to support metabolic demand. This type of failure can be divided 
further into a) systolic failure, due to the inability of the ventricle to contract normally and pump 
enough blood into the circulation and b) diastolic failure, the inability of the ventricle to relax 
before being filled with blood during the relaxation period. 
 During right heart failure, de-oxygenated blood returns from the rest of the is not 
adequately being moved for oxygenation into the lungs. Right heart failure can occur on its own 
because of issues like pulmonary hypertension or coronary disease affecting the right side of the 
heart or occur in the setting of the left-sided failure, also known as biventricular failure.  
Finally, then there is another type of failure known as Congestive Heart Failure (CHF). 
Congestive heart failure is often used interchangeably with heart failure. The blood backs up in 
the veins due to the slowing of the heart to pump blood out, causing congestion in the tissues, 
resulting in edema conditions. Unless treated promptly, this could lead to many complications. 
Apart from being a fatal phenomenon, heart failure can be expensive in terms of the direct 
and indirect costs involved with its treatment. It is therefore essential to reduce the overhead cost 
by adapting faster and more efficient treatment which is primarily the reason why much research 
is still being carried out in this field.  
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1.2.2 Treatment of Heart Failure 
According to the National Heart, Lung, and Blood Institute, early diagnosis and the 
corresponding treatment is critical for a patient with heart failure to live longer and lead a more 
active life [5]. The treatment depends on the type and severity of the failure. Essential goals for 
any stage of heart failure would be to treat the cause, reduce the symptoms, stop the heart failure 
from getting worse and help to improve the quality of life leading to an increased life span.  
Heart failure is a disease in its initial stages is often managed through lifestyle changes and 
medications [9]. However as the disease progresses, more advanced treatment becomes necessary. 
In terms of medications, the severity and the response of an individual to medications determine 
the doses prescribed. Some of the commonly used medications are ACE inhibitors, Aldosterone 
antagonists, Angiotensin receptor blockers, Beta blockers, etcetera [10].  
When heart failure worsens, tratments might involve surgeries or device based medical 
procedures. Examples of medical procedures using devices are a cardiac resynchronization therapy 
using a pacemaker, and an Implantable Cardioverter Defibrillator (ICD) which employs an 
electrical pulse depending on the heart rate to correct the irregular heart rhythm.  
Despite all these, there are still several patients who would need other forms of treatments. 
A heart transplant is the final method of treatment to save a life, in situations where a less drastic 
surgery has failed, by replacing a diseased heart with a healthy heart from a deceased donor. If 
there can be a way to avoid such a drastic measure, that is the best outcome in terms of treatment. 
In such cases, a mechanical pump, known as a Left Ventricular Assist Device (LVAD) is used 
more commonly nowadays, in different types of treatments. In this dissertation, the treatment of 
heart failure with LVADs is explored to try and understand the recovery of the ailing heart.  
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1.3 Left Ventricular Assist Devices 
  In isolated left heart disease, a continuous flow left ventricular assist device (LVAD) is 
an option for treating patients with advanced heart failure[9, 11-15]. 
For patients with advanced heart failure, the treatment options that exist are limited. When 
all other methods of treatment fail, the gold standard is the orthotropic heart transplantation[13]. 
The most significant factor that makes this a sporadic form of treatment in comparison to the 
number of eligible cases is the availability of donors’ heart. [16-18] have shown statistically that 
the number of organs available for transplantation averages around 2,100 – 2,400 every year, 
whereas the number of people experiencing heart failure is about 550,000. This stark difference 
leads to many patients who qualify for heart transplantation not ever receiving a donor organ. [17, 
19] also discuss the cases of patients with advanced HF, who have experienced a failure of optimal 
medical therapy, become ineligible for transplantation due to reasons like age, obesity, and 
complications due to long-standing diabetes.  
In such a scenario, an alternative treatment to bridge the gap between the eligible patients 
for transplantation and the availability of organs is essential. There is an ever-growing acceptance 
of using a mechanical circulatory support (MCS) device, where heart transplantation is not an 
immediate option, as a treatment of advanced HF either as a stop gap to transplant or as a more 
permanent solution for ineligible candidates. There are some studies that put forward an 
increasingly favorable argument for the use of MCS devices [20-22]. For advanced HF that is 
refractory to medical therapy [13, 23-26], the use of MCS devices has helped manage acute and 
chronic HF. These studies have made the utilization of an MCS device due to the successful 
8 
 
clinical validation conducted in several pivotal studies, which in a sense has revolutionized the 
therapy of advanced HF. One such MCS device is the Left Ventricular Assist Device.   
Left Ventricular Assist Devices or LVAD is an implantable mechanical pump that is 
connected as a bridge between the left ventricle and the aorta. The primary function of an LVAD 
is to aid the left ventricle of the patient in pumping blood in a sick heart. The pump is usually 
placed just below the diaphragm in the abdomen, with a tube passing through the skin that connects 
the pump with a controller unit and the battery pack that provides power. 
Over the past few years, the LVAD therapy has evolved in a very brisk manner and with 
the help of studies such as REMATCH Trial and INTERMACS, it has become much more reliable 
in producing data on how successful the utilization of the LVAD has been in patients [13, 21, 23, 
27-29]. INTERMACS has reported during their 7th Annual Report [28] a routine monitoring of 
15,000 patients, and another study [26] points to an even higher number of over 22,000 patients 
having an LVAD implanted with about 2,500 new implants added annually.  
Over the last decade, there has been a steady evolution of the LVAD as an implantable 
device from a volume displacement based pulsatile pump to a continuous flow rotary pump [30]. 
The continuous flow rotary pump has been linked to improved survival rate amongst patients but 
might encounter problems with the development of thrombosis. Magnetic Levitation based 
continuous flow rotary pumps have been explored to avert the problems associated with 
thrombosis [31]. Continuous flow rotary pumps can be further classified either as axial flow pumps 
or centrifugal flow pumps [13, 26, 30]. These pumps are put to greater clinical use due to the 
several positive attributes they have. These include their smaller sizes, better durability, and 
enhanced survival chances with less morbidity [21, 30]. Several studies and reviews have 
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summarized the advantages of the continuous flow rotary pumps over the pulsatile pumps, and 
also the design mechanics of both the axial and centrifugal pumps.  
1.3.1 LVAD Components 
The LVAD has the following essential components [32, 33]. 
• Inlet Cannula: It is a tube that connects the left ventricle to the pump. It is surgically 
implanted to the walls of the left ventricle. 
• Mechanical Pump: The central part of the LVAD system. Two major types exist which are 
the Pulsatile and Continuous Flow Pumps. A generic Continuous Flow Pump of the axial 
type is the pump modeled in this dissertation.  
• Outlet Cannula: A tube that connects the pump to the ascending aorta. 
• Controller: To control the motor power and speed, provide redundant system operation, 
monitor the performance of the system, records, and store events in the memory and to give 
warnings and alarms when necessary.  
• Power Source: A set of rechargeable batteries that are worn by the patient with a shoulder 
strap, acts as the power source of the LVAD.Usually, there are two batteries, one to power 
the controller unit and the other is the backup. The monitoring of the battery level is from 
the screen of the controller unit.  
• Driveline: A tube that runs from the controller unit and passes through the skin to the pump 
to provide the current needed to control the rotational speed of the pump. 
Figure 1.3 shows the schematic of an LVAD connected between the left ventricle and the 




Figure 1.3: Schematic of a rotary LVAD connected between the left ventricle and the aorta 
 (https://www.sciencedirect.com/science/article/pii/S0735109704003304#FIG1[34], Permission to Use is in 
Appendix H) 
1.3.2 LVAD Treatment Strategies 
For some patients, the LVAD is used as a bridge to transplantation and explanted when a 
donor’s heart becomes available.  For patients who are not candidates for heart transplantation, the 
LVAD may remain implanted for the rest of their lives as a destination therapy device[13, 28]. 
More recently, during the past ten years or so, the LVAD was also used temporarily as a bridge to 
recovery for some patients whose heart muscles had the potential to recover because of the help 
provided by the LVAD.  The device is typically explanted once the heart has regained its ability 
to function normally [35].  
1.4 The Cardiac Cycle 
The sequence of events related to the heart from ending of one heartbeat to beginning of 
another is known as the cardiac cycle. The cycle is split into two phases, namely systole and 
diastole, but this does not provide specifics about the valve dynamics. The other more specific 
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nomenclature which provides a good measure of the valve dynamics uses four phases [2, 36] as in 
Table 1.1.  
Table 1.1: Phases of Cardiac Cycle 
Modes Valves Phases Mitral / Tricuspid Aortic 
1 Closed Closed Isovolumic Relaxation 
2 Open Closed Filling 
1 Closed Closed Isovolumic Contraction 
3 Closed Open Ejection 
- Open Open Not Feasible 
 
Figure 1.4: Wiggers diagram of the Cardiac Cycle 
(https://commons.wikimedia.org/wiki/File:Wiggers_Diagram_2.svg, Permission to Use in Appendix I) 
Figure 1.4 shows the blood pressure and blood volume curves as well as the 




Similar phases can be seen in the right heart like that of the left heart and both happen 
simultaneously. The pressures in the right ventricle, right atrium and pulmonary artery are lower 
than that of the left ventricle, left atrium, and the aorta respectively, due to the fact the left ventricle 
needs to pump blood to the whole body whereas the right ventricle pumps blood to a specific 
organ, i.e., the lungs, thus making the left ventricle stronger.  
At this juncture, it is important to note that parameters and concepts related to the cardiac 
cycle are discussed in Appendix A are used repeatedly in this dissertation [37]. 
1.5 The Cardiovascular System Model 
There are many similarities between the flow of blood in blood vessels and the electric 
current passing through conductors. When subject to a pressure difference, the velocity of the 
blood changes, and in turn the flow rate changes. The flow rate of blood is equivalent to the current 
flowing through a resistor, which represents the resistance to the flow of blood in a blood vessel. 
In blood vessels, the inertance, which is modeled using an inductor, plays a vital role especially 
for the larger vessels and contrarily resistances have more effect for a smaller blood vessel [38]. 
The theory of the electrical analog of the circulatory system using elements of an electrical circuit 
is summarized in Appendix B.  
An entity, be it physical, mechanical, biological, physiological, or conceptual can be 
modeled using a complete and consistent set of mathematical equations [39]. A significant 
advantage of such models is that a wide range of theoretical aspects of an entity can be thoroughly 
studied before applying it to real-world applications. In engineering, such testing methods based 
on simulations help propose, modify, and improve designs, and at the same time not spend much 
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time, money, resources, effort, and in the case of medical applications, risk the loss of life. Any 
underlying changes in the entity, known as the inverse problem, may also be described using the 
input-output data relation in the model. [3] explores rapid advancement in the modeling of 
biological systems, attributing it to the use of technology to collect and process vast amounts of 
data needed to develop an accurate model.  
 
Figure 1.5: Fifth Order Circuit Model of the Cardiovascular System 
The complexity of the model is determined primarily by the application. For the purpose 
of this dissertation, only a lumped – parameter circuit model of the left side of the heart with 
systemic circulation is considered in this chapter and henceforth. In this dissertation, the lumped 
– parameter model of the cardiovascular system using the definitions of the electrical analogs 
described in Appendix B, is translated into differential equations using circuit laws [40]. The 
lumped-parameter model of the cardiovascular system as developed in [41] is shown in detail in 
Appendix C, which is used to mimic the left heart for modeling the cardiovascular-LVAD model. 
Figure 1.5 represents the electrical analog model of the cardiovascular system, specifically the left 
heart. Table 1.2 summarizes all the parameters of the model along with their physiological 
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meaning and with appropriate standard values where applicable[41-43]. [44] explains the 
parameters and provides an algorithm for the estimation process of the same. 
Table 1.2: Model Parameters 
Parameters Value Physiological Meaning 
Resistances (mmHg.s/ml)   
RS 1.0000 Systemic Vascular Resistance (SVR) 
RM 0.0050 Mitral Valve Resistance 
RA 0.0010 Aortic Valve Resistance 
RC 0.0398 Characteristic Resistance 
Compliances (ml/mmHg)   
C(t) TIME – VARYING Left Ventricle Compliance  
CR 4.4000 Left Atrial Compliance 
CS 1.3300  
CA 0.0800  
Inertances (mmHg.s2/ml)   
LS 0.0005 Inertance of Blood in Aorta 
1.5.1 Systemic Vascular Resistance 
Systemic Vascular Resistance ( )SVR , also referred to as SR  in Figure 1.5, is defined as the 
total resistance of the systemic circulation to the blood flow. When SVR increases, it increases 
arterial pressure, thereby reducing cardiac output, and vice versa [45]. The most important factor 
that affects SVR  is the overall diameter of the blood vessels in the systemic circulation. Physical 
activity can change the physiology of the circulation, therefore, during exercise, SVR  decreases, 
producing more blood flow into the circulation, and during rest, it increases [46, 47]. 
Physiologically, we can define SVR  as the ratio of the pressure difference between the 
mean arterial pressure ( )MAP  and the central venous pressure ( )CVP , which is the pressure inside 






=  (1.1) 
The value SR is used as a measure of the level of activity and after load in the simulations. 
Smaller the value, it models higher levels of activity such as fast walking or running, and higher 
values are used to model lower levels of activity such as rest or sleeping. 1.0 /SR mmHgs ml= is 
used in our model, to represent a normal level of activity, which involves minimal movement and 
not in bed rest.  
1.5.2 Left Ventricular Compliance 
The functionality of the myocardial fibers determines the ability of the left ventricle, 
viewed as a flexible pouch that expands and contracts based on the differential pressure it 
experiences. The elastance is the measure of the elasticity of these muscles, defined by the 
elastance function ( )E t . ( )E t is a time – varyingparameter that describes the relationship between 
the left ventricle pressure ( )LVP t , the left ventricular volume ( )LVV t  and a distending volume 
DV  which relates to the volume of blood available in the left ventricle when the transmural pressure 
is 0 [49-51]. 







To model the electrical analog, we represent the elastance function as its equivalent 





=  (1.3) 
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In the model to mimic the ventricular function, the elastance function is based on 
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 (1.4) 
where, maxE  is the maximum elastance, minE  is the minimum elastance, and 1 2 1 2, , , ,a n nα α  are 
shape constants. maxE and minE  are related to the end-systolic pressure volume relationship and the 
end-diastolic pressure-volume relationship, respectively.  T is the cardiac period which is 
dependent on the heart rate (HR). The  shape constants  values, as summarized in Table 1.3 are 
obtained from [52].  
Table 1.3: Shape Constants for Elastance Function 
Shape Constant Value 
a 1.672 
1α  0.303 
2α  0.508 
1n  1.32 
2n  21.9 
 
In Table 1.4, using the classification of various heart condition summarized in [53, 54], 
different cases of heart conditions used throughout the dissertation are summarized and classified. 
An maxE of 2.0 mmHg/ml or more represents a healthy heart, and any value of maxE less than 2.0 
mmHg/ml, refers to various levels of a heart failure condition. A lower value of maxE  means that 
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the ventricle is less elastic and more severe in terms of its sickness. A constant value of minE = 
0.06 mmHg/ml used throughout for all types of a heart condition. 
Table 1.4: Cases of Heart Condition 
Case Emax Heart Condition 
1 ≥2.0 Healthy 
2 1.25 – 2.0 Mild Dysfunction 
3 0.8 – 1.25 Moderate Dysfunction 
4 <0.8 Severe Dysfunction 
1.5.3 Mitral and Aortic Valves 
The diodes in the electrical model in Figure 1.4, are non – ideal, consisting of an ideal 
diode and an internal resistance. The combination of MR  and MD  represent the mitral valve and 
that of AR  and AD  represent the aortic valve. As the functions of an ideal diode go, it is either a 
short circuit or open circuit depending on the voltage across it. Thus, if the diode is a short circuit, 
the valve is open, and the diode is an open circuit for a closed valve. 
1.5.4 State Variable Model of the Electrical Analogue 
A state variable is a set of variables that are used to describe the mathematical “state” of a 
dynamical system. The state of a system is inherently described sufficiently enough by the state 
variable, that it can be used to determine its future behavior in the absence of any external forces 
affecting the system. The model described in Appendix C consists of a set of coupled, five first 
order differential equations and describes the cardiovascular system in a state – variable form. 





Table 1.5: State Variables in the Cardiovascular Model 
Variables Name Physiological Meaning (units) 
x1(t) LVP(t) Left Ventricular Pressure (mmHg) 
x2(t) LAP(t) Left Atrial Pressure (mmHg) 
x3(t) AP(t) Arterial Pressure (mmHg) 
x4(t) AoP(t) Aortic Pressure (mmHg) 
x5(t) QT(t) Total Flow (ml/s) 
 
The state variables 1x  to 4x were introduced earlier in the chapter. It is necessary at this 
stage to introduce the state variable 5x , the total flow of blood entering the arterial circulation.  
Defining the four phases of the cardiac cycle in terms of the state variables should  be the 
first step to ultimately make the model mimic the physiological parameters. Let us consider, the 
contraction and the relaxation phases. In these phases, LVP is greater than LAP and AoP is greater 
than LVP, thereby closing both the valves. From Table 1.5, we can see it translates to 1 2( ) ( )x t x t>
and 4 1( ) ( )x t x t> . Now the ramp function 2 1( )r x x−  will be 0, and so will be 1 4( )r x x− as defined 
in (C.4) and (C.6). The diodes MD  and AD act as an open circuit, respectively. When the cardiac 
cycle is in the ejection phase, 4 1( ) ( )x t x t< and the ramp function, 1 4( )r x x− , results in a value, 
1 4x x− , equal to the voltage difference across the diode AD  and its resistance AR . Likewise, we 
can see a similar effect for the mitral valve for the filling phase. Table 1.1 in terms of state variables 










Table 1.6: Phases of Cardiac Cycle in terms of State Variables 
Modes Valves – Ramp Function Value Phases Mitral / Tricuspid Aortic 
1 0 0 Isovolumic Relaxation 
2 2 1x x−  0 Filling 
1 0 0 Isovolumic Contraction 
3 0 1 4x x−  Ejection 
- 2 1x x−  1 4x x−  Not Feasible 
1.6 Simulation of the Cardiovascular Model 
The Cardiovascular Model is simulated to build reference data points for the state variables 
listed in Table 1.5, for different types of heart, both healthy and unhealthy. In order to carry out 
the simulations, the variables listed below are the ones that vary in the model to provide the 
different simulation conditions.  
The variables are,  
• The contractility, maxE .  
• The Heart Rate, HR . 
• The Systemic Vascular Resistance (SVR), SR . 
1.6.1 Elastance Function 
The heart contracting and expanding is dependent on the contractility of the heart muscle. 
In the model, the contractility of the heart is measured in terms of the elastance function, defined 
in(1.4). For the different cases in Table 1.4, the elastance function ( )E t  is simulated at a heart rate 




Figure 1.6: Ventricular Elastance Function, ( )E t , over a cardiac cycle for different maxE  
Figure 1.5 shows the plot of ( )E t . For each of the cases, the maximum of the ( )E t function 
is equal to the corresponding maxE  as mentioned. Since minE was set to a constant value, we see 
the lowest value of the ( )E t function is the same for all the cases. The peak of the ( )E t function 
for all the cases occursat 0.34t s= . The time instant at which the peak of the ( )E t function occurs 
is approximately 43% of the cardiac cycle, being the case at the different heart rates. Plots of the 
( )E t function with maxE of 2.0 mmHg/ml for 60, 75, 90 and 120 BPMs are in Figure 1.6.  


















E m a x  = 2.5 (Case 1)
E m a x  = 1.8 (Case 2)
E m a x  = 0.5 (Case 4)




Figure 1.7: ( )E t function for different Heart Rates over one corresponding cardiac cycle. 
The peak of each of the E(t) functions occurs at the time instants as summarized in Table 
1.7, which indicates the time-spatial distribution of the elastance function. 
Table 1.7: Time Spatial Distribution of Peak of ( )E t  
Heart Rate 
(BPM) 
Cardiac Cycle  
(T in s) 
Time Instant of maxE  
(t in s) 
% of T 
60 1.00 0.43 43.0 
75 0.80 0.34 42.5 
90 0.67 0.29 43.2 
120 0.50 0.22 44.0 
1.6.2 State Variables for a Healthy Heart 
The cardiovascular model was simulated for a healthy heart with maxE  of 2.0 mmHg/ml, 
with HR of 75 BPM and SR  set at 1.0 mmHgs/ml and the state variables plotted in Figure 1.7. 
Although these plots are not used directly further in the dissertation, it is essential to see that the 
model can replicate the waveforms like the ones shown in Figure 1.3. The ventricular volume 
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curve, LVV, is not a direct, measurable parameter from the model. The equation(1.2) upon 











Figure 1.8: Sample Plots of the state variables over a cardiac cycle obtained from the model. (a) Left Ventricular 
Pressure, (b) Left Atrial Pressure, (c) Arterial Pressure, (d) Aortic Pressure and (e) Total Flow. 


















































































Figure 1.9: Left Ventricular Volume Curve for one cardiac cycle. 
1.7 The Combined Cardiovascular - Left Ventricular Assist Device Model 
In this dissertation, the LVAD Pump considered is a second-generation continuous axial – 
flow blood pump that is driven by a DC motor. A combined cardiovascular – left ventricular assist 
device model is derived in [41] and the equivalent circuit is shown in Figure 1.10 Now, the total 
number of state variables become 6, which is the blood flow in the pump, PQ  .  
The motor in the pump due to the rotation of the impeller creates a pressure difference that 
enables the flow of blood[55-57]. This pressure difference is represented as the sum of the pressure 
gradients in the inlet cannula, IH  , the pump head PH , and the pressure gradient in the outlet 




















 Table 1.8: Model Parameters for the LVAD 
PARAMETERS VALUE PHYSIOLOGICAL MEANING 
RESISTANCES (mmHg.s/ml)   
Ri 0.0677 Inlet Resistance of Cannulae 
RP 0.1707 Pump Resistance 
RO 0.0677 Outlet Resistance of Cannulae 
R* 0.3061 R*=Ri+Rp+Ro 
INERTANCES (mmHg.s2/ml)   
Li 0.0127 Inlet Inertance of Cannulae 
LP 0.02177 Pump Inertance 
LO 0.0127 Outlet Inertance of Cannulae 
 




β 9.9025X10-7 LVAD Pump – Dependent Constant 
 
 
Figure 1.10: Electrical Circuit Equivalent of the Combined Cardiovascular - LVAD Model. 
Table 1.6, shows the updated state variables. The combined Cardiovascular – LVAD 




Table 1.9: State Variables for the Combined Cardiovascular – LVAD model 
VARIABLES Name PHYSIOLOGICAL MEANING (UNITS) 
x1(t) LVP(t) LEFT VENTRICULAR PRESSURE (mmHg) 
x2(t) LAP(t) LEFT ATRIAL PRESSURE (mmHg) 
x3(t) AP(t) ARTERIAL PRESSURE (mmHg) 
x4(t) AoP(t) AORTIC PRESSURE (mmHg) 
x5(t) QT(t) TOTAL FLOW (ml/s) 
x6(t) QP(t) PUMP FLOW (ml/s) 
1.8 The Pump Model 
The level of support provided by the LVAD is usually controlled using the speed of the 
pump. Extending the lumped parameter model of the cardiovascular system, a LVAD supported 
heart can be modeled using the same method as in Appendix C and with the additional parameters 
described in Table 1.8 to describe the various components of a LVAD. The model equation of the 
combined cardiovascular – LVAD model can be summarized as in Equation (1.5).  
The detailed derivation of the model is in Appendix D. Equation (1.5) models a generic 
continuous flow axial pump, with the control input being the speed. The model shown in Equation 
(1.5) is what will be further used to study the volume of blood and characterize it between the heart 
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 (1.5) 
1.8.1 Advantages and Limitations of the Model 
The combined cardiovascular – LVAD model has been thoroughly validated to provide a 
good equivalence to parameters measureable to humans. The advantage of using a model is the 
ability to test a wide range of possible scenarios and understand variables that cannot be easily 
measured without a complex procedure. Ventricular elastance is not easily measured or monitored 
without invasive procedures, and is measured using other parameters. Whereas, the model allows 
to study the changes in the physiological state with respect to a change in elastance. This allows 
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for a possibility of studying parameters that might not be easily studied in a clinical setting. In case 
the patient after treatment is showing progress simulation of the model will help to provide the 
data that a physician might require but would not be able to measure.  
There are obvious limitations to the model. The model is not specific to a patient. The 
elastance function used provides a fixed curve depending solely on the shape constants and the 
maximum and minimum values. It does not take into effect any instantaneous changes to the LVP 
and Left Ventricular Volume. In heart failure patients in practice, the LVP tends to vary according 
to the circulation. There is no feedback mechanism on the physiology that modulates the LVP, 
which thereby is not translated into the elastance. On the other hand, the Left Ventricular Volume 
might also be affected by the ability of the ventricle to unload, causing an instantaneous change in 
the elastance and subsequent pumping.  
Although the model depicts physiology very accurately, in practice when an LVAD is 
implanted it might affect the aortic valve opening and cause an irregular opening and closing of 
the valve. It means, the valve might open and close for a particular cardiac cycle and be shut for 
the next few cycles before it reopens. These pertain to the same reasons attributed in the previous 
paragraph regarding LVP and also in addition to the factors governing the AoP.  
A more comprehensive model which not only includes the left heart but also the rest of the 
circulatory system, including the pulmonary circulation, and the autonomous control system would 
be able to bridge the gap to an actual clinical scenario, but for the current study such a model is 




CHAPTER 2  
HEART AND PUMP – BLOOD VOLUMES 
One of the parameters measured in fluidic transport is flow. Newtonian fluidics are 
categorized by the stresses and strains in the flow of the fluid. Blood, categorized as a non-
Newtonian fluid, differs in properties which are dependent on the flow of the fluid[61].  
Techniques using transesophageal ultrasonic echo-Doppler to measure the aortic blood 
flow rate to provide continuous monitoring [62-64]. These techniques still require a patient to be 
hospitalized, given anesthesia to carry out the procedure. Other methods such as PET, radionuclide 
scan, colored microspheres, MRI scans can be used to measure the flow rate [64-67]. It therefore 
becomes imperative to look at an alternative non-invasive method which would not only result in 
a reduction of cost, but also improve the logistics surrounding any therapy.  
Several techniques using optical methods, acoustic methods, etc. can be used to measure 
the changes in blood volume non-invasively. Photoplethysmography [68-70], ICG Pulse 
Spectrophometry[71] and a non-invasive method shown in [72] are some of the methods that can 
be feasibly used to measure blood volume as well as various other physiological parameters. The 
procedure to measure blood volume as compared to the ones to measure blood flow rate might be 
simpler and cost-effective, with no major hospitalization required.  
Studies have shown that aortic valve dynamics play an important role in the recovery of 
the heart. Normal dynamics of the aortic valve means, the regular opening and closing of the aortic 
valve during a cardiac cycle. The speed of recovery of the heart may depend on the dynamics of 
the aortic valve. Some of the studies have credited the normal dynamics of the aortic valve to the 
recovery of the heart. An engineering analysis of the same has been discussed in [73, 74]. 
29 
 
Several strategies have been used by many research groups to study the dynamics of the 
aortic valve such as continuous echocardiography monitor [75], direct measurement of AoP using 
Millar catheter [76], delayed copulse mode based on the LVAD rotational speed [77], and modified 
Karhunen-Loeve transformation with LVAD current waveforms [78]. 
The main purpose of this chapter is to use the aortic valve dynamics to study the different 
ejection paths, namely one through the aortic valve and the other through the LVAD, the effect of 
the LVAD speed, the contractility and also the instantaneous volume of the left ventricle during a 
cardiac cycle. The idea behind shifting the study from a flow based analysis to a volume based 
analysis is to ensure that clinical measurements can be made more robust and less invasive to deal 
with volume and also to understand in close to real time, ventricular functions using simple 
measureable parameters.  
2.1 Simulation Results 
In this dissertation, to study the blood flow and volume profiles through both the heart and 
the pump, the simulation was performed both on an unassisted sick heart and an LVAD assisted 
sick heart. For the unassisted sick heart, the model with no LVAD was simulated and for the 
assisted heart, simulations were done using the 6th order model using MATLAB® (Natick, MA, 
USA). The control variable for the pump, in the case of assisted heart simulations, have been 
considered to be both the Pump Speed and Pump Power.   
To simulate the sick heart, the contractility of the sick heart according to the various 
degrees of sickness is as shown in Table 1.3. The other variable parameters are defined in relation 
to the different cases summarized in Table 2.1. In the table, HR is the heart rate of the sick heart 
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in BPM, RS the systemic resistance measured in mmHgs/ml. The systemic resistance is the 
measure of the activity level of the heart. The activity level of the heart is as classified in Table 
2.1. 
Table 2.1: Parameters Used for Simulation 
Sub-Case* HR RS 
I 60 1.25 
II 75 1.0 
III 90 0.75 
IV 105 0.625 
V 120 0.5 
*- The Sub-Case will be mentioned with brackets when discussing simulations.  
2.2 Aortic Valve Flow and Volume 
The opening and closing of the aortic valve are governed by the Left ventricular pressure, 
( )LVP t  and the aortic pressure, ( )AoP t . The aortic flow is characterized by the resistance of the 
valve, namely the aortic valve resistance, AR . Aortic valve flow, ( )AVQ t  is expressed as, 
 ( ) ( )( )AV
A
LVP t AoP tQ t
R
−
=  (2.1) 
The aortic valve flow is then integrated over the interval in which the aortic valve is open, 







V Q t dt= ∫  (2.2) 
The volume of blood ejected through the aortic valve is the volume contributed by the heart 
when the LVAD is present. Of the total blood ejected in such cardiac cycle, a portion of the ejection 
is contributed by the heart and the pump contributes the rest.  
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The flow of blood ejected through the aortic valve, can be obtained using (2.1). Figure 2.1 
plots ( )AVQ t  for an unassisted sick heart for a heart rate of 75BPM and SR  = 1.0, simulating an 
equivalent of Case 3(II). The contractility of the heart has been varied to simulate different levels 
of heart failure.  
 
Figure 2.1: Aortic Valve Flow over one cardiac cycle for Unassisted Heart, Case II, for different maxE . 
It can be observed that upon opening of the aortic valve, there is ejection of blood through 
the valve, almost instantaneously. The rate increases to touch a peak and then starts to fall 
eventually to 0 ml when the valve closes. Given that HR is 75BPM, the cardiac period is T  = 
0.8sec. The volume of blood being ejected during this one cardiac cycle, AVV , calculated using the 
equation(2.2). The various parameters, at (s), bt (s), peak flow (ml/s), AVV (ml), the percentage of 
time the aortic valve is open during a cardiac cycle and the cardiac output (L/min) are all noted for 
the plots shown in Figure 2.1, in Table 2.2.  
 

























m a x  = 0.75
E m a x  = 0.5
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Table 2.2: Flow Parameters from Figure 2.1 
maxE  at  bt  %VO  Peak Flow AVV  CO  
1.5 0.087 0.363 34.50 428.37 58.39 4.38 
1.0 0.104 0.365 32.62 326.78 48.86 3.66 
0.75 0.113 0.368 31.87 266.78 41.75 3.13 
0.5 0.127 0.371 30.50 195.34 31.76 2.38 
 
The data from Table 2.2, indicates that as the contractility decreases, representative of a 
worsening heart failure, the total time for which the valve is open during a cardiac cycle decreases, 
which can be observed with the percentage of time the aortic valve is open during a cardiac cycle 
(%VO). When the heart failure is mild as in the case with maxE = 1.5, the volume of blood 
traversing through the aortic valve is higher.  
In comparison with a healthy heart, the unassisted sick heart falls short of meeting the needs 
of a human body, when all other parameters are kept constant. This shortage is essentially what 
the LVAD tries to fill in. At the same time, implanting the LVAD will alter the way the native 
heart works, similar to any mechanical system working based on the principle of pressure head 
difference.  
The aortic flow for all the simulations as done in Table 2.2 with LVAD input speed of 
4000RPM is simulated to compare. The result of the flow through the aortic valve is shown in 
Figure 2.2.  
Similar to the unassisted heart simulations, we can see that the blood flow follows the same 
profile. To compare the data, the same parameters measured in Table 2.2, were recorded and 





Table 2.3: Flow Parameters from Figure 2.2 
maxE  at  bt  %VO  Peak Flow AVV  CO  
1.5 0.112 0.342 28.75 287.87 31.51 2.36 
1.0 0.143 0.348 25.62 185.26 21.21 1.59 
0.75 0.172 0.351 22.38 126.29 13.96 1.05 
0.5 0.243 0.352 13.62 47.23 3.40 0.26 
 
 
Figure 2.2: Aortic Valve Flow over one cardiac cycle for an Assisted Heart for Case II. 
Upon implanting the LVAD, the flow of blood through the LVAD changes the aortic 
pressure due to the presence of the impeller, as can be seen from equation (D.1) from Appendix 
D. The aortic valve opens and closes due to the pressure difference between the Left Ventricular 
Pressure (LVP) and the Aortic Pressure (AoP), which is indicative of the flow in the aortic valve. 
The LVAD elevates the aortic pressure, a factor in changing the dynamics of the aortic valve as 
discussed in [74]. 
Simulations show that the combined system consisting of the heart and LVAD in general 
follows the patterns as observed in Table 2.2. The higher contractility state certainly has better 
values in terms of %VO , Peak Flow, AVV  and CO .  The following observation can be made while 
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comparing Table 2.3 and Table 2.2. In all, the aortic valve is open for a shorter period of time 
when an LVAD is implanted, thereby indicating that the LVAD does alter the dynamics of the 
aortic valve, which can be seen in %VO  data, as has been previously summarized in [74] . The 
flow through the aortic valve will also be reduced with the LVAD implanted and for the same 
contractility, the Peak Flow and subsequently AVV shows reduced levels when compared with data 
in Table 2.2. For the case with maxE  of 1.0, the Peak Flow when there is no LVAD is 326.78 ml/s 
(Table 2.2) and with LVAD it reduces to 185.26 ml/s.  
For the unassisted sick heart, AVV  is also the stroke volume, which is 48.86 ml for the 
above – mentioned case of contractility and with the introduction of the LVAD, the volume of 
blood ejected through the aortic valve, AVV  reduces to 21.29 ml. 
2.3 Pump Flow and Volume 
The model discussed in Chapter 1 (shown in Figure 1.7) incorporates a continuous flow 
pump (a generic axial flow pump) and pump flow, ( )PQ t , is a state variable, as shown in Table 
1.5. Pump flow is a function of the input of the pump. Initially, the input discussed is the pump 
speed.  
By design a continuous flow pump ejects blood throughout a cardiac cycle. To find the 
volume of blood ejected through the pump, pump flow, ( )PQ t , is integrated over the entire cardiac 
cycle [0, ]T , where T is the cardiac cycle duration. Let LVADV  represent the volume of blood ejected 







LVAD PV Q t dt= ∫  (2.3) 
The pump flow is obtained by solving the differential equations ( 6 ( )x t ). Figure 2.3 
illustrates the variations of pump flow for three values of input power {2000,4000,8000}RPMω =
for Case 3(II). The pump flow has the superposed oscillatory component which follows the 
pulsatility of the heart, thus affecting the performance of the pump [79]. The mathematical model 
used has been shown to replicate this phenomenon [62]. It is thus observed that the model clearly 
simulates a complex biological system.  
 
Figure 2.3: Pump Flow for Different Input Pump Speed 
Referring back to the different phases of the cardiac cycle, it was understood that the 
development of LVP and AoP happens during the isovolumic contraction, although AoP is higher 
than LVP. At this juncture, it has to be kept in mind that the LVAD branch is currently operating. 
The cause of blood flowing through the LVAD pump is due to the pressure difference that occurs 


























between the inlet cannula and outlet cannula of the pump [21]. This pressure difference is known 
as the pump pressure head. LVP directly affects the pressure at the inlet cannula side of the pump.  
As the LVP increases, other than the unloading of the ventricle due to the pump, the 
contraction in the ventricle pushes more blood into the pump. This means, that the pump flow 
profile shown in Figure 2.3, is made up of two components, which is named as,  
• Pump Flow Due to Heart Contraction (HPF) – This is not going to be a constant and will 
vary depending on the pressure developed in the ventricle.  
• Pump Flow Due to Pump Impeller (CPF) – This is a constant flow, and the rate of flow is 
dependent on the control input of the LVAD pump.  
The pump flow over one cardiac cycle is plotted in Figure 2.4, which is for a pump speed 
of 4,000RPM. The plot shows that the pump flow does not go to 0 at any point. This is expected 
given that the pump is a continuous flow pump. The volume of blood that passes through the 
LVAD is found using equation (2.3). In MATLAB®, the flow as shown in Figure 2.4, is time step 
integrated using trapezoidal rule, at a time step of 0.0001s between the time interval[ ]0,  0.8 s . The 
time step is maintained constant irrespective of the heart rate, whereas the cardiac cycle interval is 
dependent on the heart rate. The volume of blood LVADV , calculated this way provides the quantity 
of blood flowing through the LVAD over a cardiac cycle, which is essentially finding the stroke 
volume of the LVAD. Since the LVAD does not necessarily work on pulsations of the heartbeat, 
representing it as a stroke volume will not be applicable.   
LVADV is calculated to be 31.43 ml. As introduced, this volume of blood is due to both HPV 
and CPV. It is therefore important to study the exact amount of blood that flows through the LVAD 
due to both HPF and CPF. We have seen that the LVAD pumps blood throughout the cardiac 
37 
 
cycle, but the component HPF is mainly due to the contraction phase of the cardiac cycle. The 
flow of blood, ( )AVQ t  and ( )PQ t is superimposed in Figure 2.5 to observe how ( )PQ t  follows 
( )AVQ t in terms of the time events during a cardiac cycle. 
 
Figure 2.4: Pump Flow for Speed of 4,000 RPM over one cardiac cycle. 
The pulsatility of the pump flow begins at an earlier time as compared to the aortic valve 
opening, and ends later than the time at which the aortic valve closes. This correlates more to the 
time interval in which the LVP is greater than its filling pressure, which is the pressure that the left 
ventricle is at when the mitral valve opens to fill it with blood from the atrium. In order to find the 
time interval for which the LVP is above the filling pressure, the slope of the LVP curve is used 




ε= ∀ >  (2.4) 
The parameter ε  is a very low positive number (usually in the order of 10-4), as the slope 
of LVP is never 0, even during the ventricular filling phase. PFT is time (t) range which satisfies 



















the equation (2.4) during which the pulsatile component of PQ , HPF, occurs mainly due to the 
influence of the heart.  
 
Figure 2.5: Comparison of the flow of blood through both the aortic valve and the pump during a cardiac cycle. 
From Figure 2.4, it is clear that ( )PQ t has an offset throughout the cardiac cycle. This offset 
in the flow is the constant flow that goes through the LVAD due to the impeller or CPF. 
The plots of HPF and CPF are shown in Figure 2.6. The influence of the heart in this case 
occurs for the time range [0,0.5]PFT s= . CPF has a value of 22.5 ml/s throughout the cardiac cycle, 
which is then subtracted from ( )PQ t  over PFT  to find HPF. It can be seen that towards the end of 
this time range, HPF goes negative for a bit. This is indicative of a reverse flow of blood from the 
LVAD to the ventricle. 
Earlier, LVADV  was found using (2.3). This, in essence, is the total integral of the pump flow 
which covers both the HPF and CPF. The individual volumes of HPF and CPF can be further 
defined as  





























V CPF t dt= ∫  (2.6) 





Figure 2.6: (a) Plot of HPF over the time interval PFT  and (b) Plot of CPF over the time interval PFT . 
It is still necessary to test (2.7), for which the same example that has been used is 
considered. Using (2.5), it is found that PHV  is equal to 13.57 ml and PCV is 17.86 ml. The sum of 
these two provides 31.43 ml, which is equal to LVADV . 


































2.4 Characterization of Volume Ejected Over a Cardiac Cycle 
2.4.1 Variation Associated with the LVAD Speed 
Figure 2.7: Pathways of blood flow with LVAD implanted. 
Figure 2.7 represents the two pathways of blood flow that is available for a heart supported 
with LVAD. One is the direct ejection from the ventricle to the aorta (Path 1) as noted by the blue 
arrows from the ventricle to the aorta, and the second being the branch of blood that goes through 
the pump (Path 2). Thus, the total volume, TV , of blood ejected in a cardiac cycle is defined as 




















The idea described in (2.9) is one way of looking at the total volume of blood, just in terms 
of the pathways. For Case 3(II), at a speed of 4,000 RPM, AVV is 21.29 ml, LVADV equals 31.43 ml 
and TV is 52.72 ml. To verify if this is true, we can obtain the total volume of blood that enters the 
aorta by adding ( )AVQ t  and ( )PQ t  together and then take the time integral of the same. The total 
volume calculated that way is 52.70 ml. It is, therefore, possible to look at the total volume of 
blood ejected in a cardiac cycle using (2.8).  
Since the LVAD flow changes with speed, it is essential to understand the influence it has 
on the volume of blood that enters the aorta for every cardiac cycle, and also compare the two 
pathways. For this, the speed of LVAD was changed from 2,000RPM to 8,000RPM for the 
conditions mentioned by Case 3(II), in steps of 100RPM and the volumes are plotted in Figure 2.8  
 
Figure 2.8: Plot of AVV , LVADV  and TV  for Case 3(II) for different LVAD speeds. 
At a speed of 2,000RPM, we see that the amount of blood that enters the aorta through the 
aortic valve is higher than the contribution of blood through the pump path. AVV is noted to be 
36.83 ml, LVADV  is 13.38 ml and TV  is 50.21 ml. For Case(II), the unassisted heart provided 48.86 
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ml of blood per cardiac cycle. The introduction of the LVAD provides the sick patient with 
additional blood as demonstrated above. Further discussions about the support provided by the 
LVAD is covered in Chapter 4. For now, the discussion is purely about the relationship between 
the speed of the LVAD and the different volumes.  
As the speed of the LVAD increases, the support provided by the LVAD increases [21, 
80]. Increasing the speed of the LVAD increases the afterload, which, in effect, increases the 
AoP[81]. AVV decreases gradually and reaches 0 at a certain critical speed, where the AoP is always 
higher than the LVP, and the aortic valve shuts down permanently [82]. The permanent closure of 
the aortic valve could lead to significant changes in the circulation physiology and complications 
such as stasis of flow in the aortic root [83], thrombus formation [84], commissural fusion [85], 
and occurrence of progression of aortic insufficiency [77, 86-88], which are detrimental to cardiac 
recovery. The speed at which the permanent closure of the aortic valve occurs is at 6,700RPM.  
The volume of blood going through the LVAD keeps increasing as the speed increases. As 
the speed approaches 6,700RPM, we can observe that the LVAD entirely takes over the ejection 
of blood from the ventricle as the aortic valve permanently shuts down. The total volume of blood 
ejected over a cardiac cycle shows a very marginal increase during the time the aortic valve is open 
even as the speed of the LVAD increases, due to the decrease in the volume of blood ejected 
through the aortic valve. In other words if T LVADV V= , then that condition means the permanent 
closure of the aortic valve.  
The different cases mentioned in Table 1.4, are also simulated. For Case 1(II), an maxE of 
2.1 mmHg/ml is used. The range of speed is between 2,000RPM to 10,000RPM. The plots for 




Figure 2.9: Plot of AVV , LVADV  and TV  for Case 1(II) for different LVAD speeds. 
According to Table 1.4, the maxE consideration would be in the range of a healthy heart 
when in general no LVAD would be required. Even in this case, the aortic valve is seen to close 
at a speed of 9,100RPM permanently. Given that the heart is in a better condition, the speed of 
2,000RPM produces blood at volumes of, AVV equal to 53.52 ml, LVADV equaling 13.19 ml and TV
totaling 66.71 ml.  
Next, for Case 2(II), the maxE of 1.5 mmHg/ml is set. The LVAD simulated between 
2,000RPM to 9,000RPM. The plots for AVV , LVADV  and TV are in Figure 2.10. 
In this case, the aortic valve closes permanently at a speed of 8,000RPM. The heart is at a 
moderate failure, thereby being able to support itself better. At low speed of 2,000RPM, AVV  is 
46.46 ml, LVADV  is 13.20 ml and TV adds up to 59.66 ml, showing the heart is still able to do more.    
























Figure 2.10: Plot of AVV , LVADV  and TV  for Case 2(II) for different LVAD speeds. 
For Case 4(II), mimicking the worst of the heart failure cases, the speed of LVAD is set 
between 2,000RPM and 8,000RPM. The maxE is set at 0.5 mmHg/ml. The plots for AVV , PV  and 
TV  for this case are shown in Figure 2.11.   
 
Figure 2.11: Plot of AVV , LVADV  and TV  for Case 4(II) for different LVAD speeds. 
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The permanent closure of the aortic valve occurs at a much lower speed of 4,400RPM. The 
volume of blood that gets ejected through the aortic valve, AVV is 19.07 ml at a speed of 2,000RPM, 
LVADV is 14.39 ml and the total volume of blood ejected is TV equal to 33.46 ml.  
Comparing the four cases, one thing that stands out is that LVADV  at a speed of 2,000RPM 
for all the cases is almost a constant. For Cases 1 – 3(II), the value hovers around 13 ml and for 
Case 4(II) the value is slightly over 14 ml. Although the LVAD support at a low speed is almost 
similar in all the cases, it indeed allows a volume of blood to be ejected through the LVAD pathway 
depending on the state of the heart. This is the reason why it becomes vital that the volume of 
blood ejected through the LVAD is further characterized using (2.7).  
Using (2.7) in (2.8), the total volume of blood ejected over a cardiac cycle can be rewritten 
as,  
 T AV PH PCV V V V= + +  (2.10) 
This further is expressed as, 






V Q t dt HPF t dt CPF t dt= + +∫ ∫ ∫  (2.11) 
T LVADV V= when the aortic valve is permanently closed. It does not mean the heart has 
stopped pumping blood. Equation (2.11) still has a component of blood that the heart pushes 




Figure 2.12: Plots of PCV  and PHV  for Case 3(II) at different LVAD speeds. 
The plots of PCV and PHV  in Figures 2.12 – 2.15 show that at no point does the heart stop 
providing blood through the pump and the influence of the heart is more prominent during the 
lower speeds of the LVAD. In Case 3(II), shown in Figure 2.12, we can see that until 3,100 RPM, 
PHV  is higher than PCV . In general, PHV , the volume of blood in the LVAD due to the heart 
influence increases with a positive slope to reach a peak, at the point where the aortic valve 
permanently shuts down, beyond which it takes a sharp negative slope.  
























Figure 2.13: Plots of PCV  and PHV  for Case 1(II) at different LVAD speeds. 
In contrast, PCV  keeps increasing just as anticipated with the LVAD speed. Till the point 
where PCV  becomes greater than PHV , it does seem that the heart affects the curve of PCV , causing 
a small dip in its slope despite it being positive right through the range of speed.  
From Figure 2.12, for Case 3(II), at a speed of 2,000RPM, 5.29 ml of blood is ejected 
through the LVAD due to the heart influence, PHV , whereas 8.09 ml of blood is the constant 
volume of blood ejected through the LVAD, PCV . The peak in the curve of PHV , which occurs 
around the speed of 6,700RPM, the speed at which the aortic valve permanently closes, is at a 
value of 17.83 ml. At the same speed, PCV produces 39.66 ml. 
The values for the other cases along with the speed at which the aortic valve gets 
permanently closed are summarized in Table 2.4. The speed at which the contribution of PCV and 
PHV are equal is also noted, along with the volume at that speed. 




















Figure 2.14: Plots of PCV  and PHV  for Case 2(II) at different LVAD speeds. 
 
Figure 2.15: Plots of PCV  and PHV  for Case 4(II) at different LVAD speeds. 
Table 2.4: Data Points From Figures 2.12 – 2.15. 
Case 
PHV (ml) PCV (ml) Speed (RPM) 
PCV = PHV (ml) 2,000RPM AV Closure 2,000RPM AV Closure 
1(II) 4.04 23.85 9.15 54.07 4,300 16.60 
2(II) 4.45 21.19 8.77 48.10 3,800 14.44 
3(II) 5.29 17.83 8.09 39.66 3,100 11.49 
4(II) 7.19 11.13 7.19 25.91 2,000 7.19 








































It is interesting to note that, when the condition of the heart is better, it is anticipated that 
the heart might influence to push more blood into the LVAD branch at all speeds. The data from 
Table 2.4 shows otherwise. When the heart is close to being healthy, as in Case 1(II), at low speeds, 
the native circulation branch can do more work, which makes the LVAD supplement very little, 
this could be due to the heart being able to produce enough pressure by itself to allow the aortic 
valve to open and close. The data shows that the pressure that the ventricle develops makes little 
influence on the pressure head at the inlet cannula. Most of the pressure head that is developed 
results in the constant flow of blood due to the impeller. Only when the condition of the heart 
worsens, the pressure head seems to be the higher driving force for blood to be ejected. The 
volume, PHV , as can be noted increases at 2000RPM for the conditions of the heart where the heart 
failure worsens.  
2.4.2 Blood Volumes – An Analytical View 
The need for having a robust mathematical model for specific physiological function 
allows the study of the various intricacies of the interactions between various systems and 
subsystems. A significant problem such mathematical models can help solve would be to assess 
patient-specific physiological function to adapt to clinical settings.These mathematical models can 
not only be used to quantify interactions; they may also be used to predict responses resulting from 
various factors that influence the system [89].  
Analytical models help exploring specific hypotheses by applying these factors to the 
discussion on blood volumes taken up in the previous section. One such hypothesis would be to 
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understand the recovery of the heart when implanted with an LVAD, specifically in answering 
question, “When is the appropriate time to wean an LVAD?”.To arrive at an optimum answer the 
study of blood volumes become a critical parameter [90, 91]. In the methods elucidated, the goal 
is to mix support of heart failure patients with an LVAD and pharmacological interventions to 
maximize the incidence of recovery and improve the durability of recovery after explantation[92]. 
The monitoring aspect of the studies to judge the explantation time are usually performed using 
echocardiograms, and the 6 – minute walk test. One of the criteria used is the assessment of the 
ventricular function. The measurement of the volume of blood ejected from the ventricle, one of 
the measures to study ventricular function, is done using angiocardiograms and echocardiography 
in terms of the diastolic and systolic diameters [93-97].  
If there could be a way that the volume of blood, especially the volume of blood ejected 
can be estimated in the presence of LVAD without extensive measurements, the monitoring of 
recovery could become robust. Thus far, the various parameters that would be forming the basis 
to study recovery have been discussed in the previous section. 
2.4.2.1 A Linear Equation Regression Model – Can it fully represent an analytical model of 
Volumes? 
In this section, the simulations would be used to develop analytical models for the various 
volumes, AVV , PV , PHV  and PCV . These volumes vary with the speed of LVAD and contractility 
of the heart, which so far has been discussed in terms of what levels of support occur at 2000RPM. 
A detailed discussion of the variation of blood volumes with contractility will be in Section 2.4.3.  
Recalling Figure 2.8, AVV appears to be following a linear relationship in the range of speed 
where the aortic valve is open and then becomes 0. Curve fitting using linear regression based on 
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the least squares method is used to fit a curve for AVV , initially as a function of the speed of LVAD 
[98-101]. The Curve Fitting Toolbox in MATLAB® is used to find the fit [102] and done 
individually for each maxE considered for the different cases in Figure 2.8 – 2.11. 
For a bridge to recovery as discussed, it is vital that normal dynamics of the aortic valve is 
ensured, meaning the speed of the LVAD will be such that the aortic valve is always open. For 
Case 3(II), the aortic valve closes above the speed of 6,700RPM. The simulation is rerun for speeds 
between 2,000 and 6,700 RPM, and the plot in Figure 2.16 ( )AVV seems to follow a linear 
relationship.  
 
Figure 2.16: Linear Regression Fit ˆAVV  compared with AVV  
A linear regression fit using a linear least squares method was employed to arrive at the 
equation (2.12).  
 ˆˆ ˆAVV az b= +  (2.12) 


























AVV is the volume of blood ejected through the aortic valve derived using a curve fit, and 
â , b̂  are the fitted polynomial constants obtained using the least squares method, and the variable
z  is a weight for the variable, speed ( )ω ,calculated by normalization over the mean of the range 
of speed ( )µ and the standard deviation ( )σ as, 
 z ω µ
σ
−
=  (2.13) 
Table 2.5 provides a summary of the curve fit extended to all the Cases. As a standard 
approach, the goodness of the fit is measured using the parameters: Sum of Squares Due to Error 
(SSE) [103], 2R , adjusted 2R [104-106] and Root Mean Square Error (RMSE)[107]. A detailed 
introduction to these parameters is given in Appendix E. The parameters â and b̂ are arrived with 
a 95% confidence bound, and the range for these two parameters is mentioned within braces in 
Table 2.5. 
Table 2.5:Linear Regression Model Fit Parameters and Goodness of fit for ˆAVV . 
Case 1(II) 2(II) 3(II) 4(II) 
















ω  [ ]2000,9000  [ ]2000,7900  [ ]2000,6600  [ ]2000,4300  
µ  5500 4950 4300 3150 
σ  2064 1746 1371 707.1 
SSE 4.79 1.93 0.56 0.02 
2R  0.99 0.99 0.99 1.00 
Adjusted 2R  0.99 0.99 0.99 1.00 





Figure 2.17Linear Regression Fit L̂VADV  compared with LVADV  
Similar to AVV , a linear fit for LVADV can be obtained as shown for Case 3(II) in Figure 
2.17. The linear regression fit is represented as,  
 ˆˆ ˆLVADV cz d= +  (2.14) 
L̂VADV is the volume of blood ejected through the LVAD found using a curve fit, and ĉ , 
d̂  are the fitted polynomial constants which are found using the least squares method and the 
variable z , is a weight calculated using the definition in (2.13).  
Table 2.6 provides a summary of the curve fit extended to all the Cases. The parameters ĉ  
and d̂  are arrived with a 95% confidence bound, and the range for these two parameters is 
mentioned within braces in the Table. 
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The linear fit is for the range of LVAD speeds where the aortic valve will have some normal 
dynamics. It is safe to say that both AVV  and LVADV  is well represented by the fits. The SSE for 
both in Cases 1(II) and 2(II) are higher than the other two cases, meaning that the fit might have 
volumes that are prone to more erroneous calculations in these two cases than the rest, yet the 2R  
and RMSE values are tolerable. 
Table 2.6: Linear Regression Model Fit Parameters and Goodness of fit for L̂VADV . 
Case 1(II) 2(II) 3(II) 4(II) 
















ω  [ ]2000,9000  [ ]2000,7900  [ ]2000,6600  [ ]2000,4300  
µ  5500 4950 4300 3150 
σ  2064 1746 1371 707.1 
SSE 3.09 1.66 0.59 0.01 
2R  0.99 0.99 0.99 1.00 
Adjusted 2R  0.99 0.99 0.99 1.00 
RMSE 0.21 0.17 0.12 0.02 
 
The next step would be to fit PCV  and PHV  using a linear curve, to generalize all volumes 
to curves of the same degree. The difficulty though appears that PHV would not be easy to fit using 
a linear equation, as observed in Figures 2.12 – 2.15. The argument about the SSE from Tables 2.5 
and 2.6 could also warrant a need to look at a fit that reduces the SSE and also establish a universal 
order fit that describes all the volumes. Therefore, it might be relevant to look at a possible 




2.4.2.2 A Cubic Regression Model  
For Case 3(II), in the speed range considered in Table 2.6, PHV  appears to follow either a 
2nd degree or a cubic polynomial curve. Applying linear regression methods for a 2nd-degree 
polynomial, SSE is found to be 0.01, 2R  and adjusted 2R  are both 1.00 and the RMSE obtained 
is 0.01. The fit parameter for a cubic polynomial turns out to be SSE of 0.01, 2R  and adjusted 2R  
are both 1.00 and RMSE is 0.01. While checking for the goodness of fit for the other cases, a 2nd-
degree polynomial was comparatively better with SSE and RMSE as compared to a cubic 
polynomial, whereas both 2R  and adjusted 2R were both 1.00 for every case. The difference in 
the SSE and RMSE were within a tolerable limit, indicating that either of the models would work. 
Table 2.7 summarises, the goodness of fit parameters for PHV . An additional parameter, DFE is also 
included, which is known as the Degrees of Freedom of Error. DFE indicates the number of 
independent components that are needed to be known to determine a fit completely.  
In the instant where either the 2nd-degree polynomial and cubic polynomial provide a good 
fit within a reasonable difference in the goodness of fit parameters for all the cases, the DFE does 
play a role in determining which of the fit parameters could reproduce the data with lower 
independent components.  
Similarly, the other component PCV is fit with a 2nd degree and cubic polynomials. The 
goodness of fit for the Case 3(II) for a 2nd degree polynomial read as SSE equals 0.47, 2R  and 
adjusted 2R are 0.99 and RMSE equals 0.10. Comparatively, for a cubic polynomial, SSE drops 
down to 0.01, 2R and adjusted 2R change to 1.00 while RMSE also drops to 0.02. Table 2.8 is 
created to summarize the goodness of fit parameters as in Table 2.7 for PCV  .  
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From Table 2.7, the observation is that there is not a significant difference in fitting PHV
either as a 2nd degree polynomial or a cubic polynomial. The DFEs are lesser for the cubic 
polynomial in both Tables 2.7 and 2.8, meaning the number of independent components that are 
needed to describe the fit is lesser for the cubic polynomial. Table 2.8, makes a case for a cubic 
polynomial much clearer, wherein all the goodness of fit parameters for all the cases are much 
better as compared to a 2nd-degree polynomial. 
Table 2.7: Comparison of the goodness of fit for PHV between 2nd-degree and cubic polynomials 
Fit Order 2nd degree Cubic 
Case 1(II) 2(II) 3(II) 4(II) 1(II) 2(II) 3(II) 4(II) 
SSE 0.04 0.02 0.01 0.00 0.03 0.03 0.01 0.00 
2R  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Adjusted 2R  1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
RMSE 0.03 0.02 0.01 0.01 0.02 0.02 0.01 0.00 
DFE 68 57 44 21 67 56 43 20 
 
Table 2.8: Comparison of the goodness of fit for PCV between 2nd-degree and cubic polynomials 
Fit Order 2nd degree Cubic 
Case 1(II) 2(II) 3(II) 4(II) 1(II) 2(II) 3(II) 4(II) 
SSE 3.29 1.57 0.47 0.01 0.10 0.04 0.01 0.00 
2R  0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 
Adjusted 2R  0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 
RMSE 0.22 0.17 0.10 0.03 0.04 0.03 0.02 0.01 
DFE 68 57 44 21 67 56 43 20 
 
Thus, the linear regression model for PHV  can be summarized as in equation (2.15) and for 
PCV in equation (2.16), 




 3 21 2 3 4P̂CV z z zυ υ υ υ= + + +  (2.16) 
where, z is the weight of the speed normalized about its mean, &i iψ υ  are the polynomial 
parameters for 1, 2,3, 4i = P̂HV  and P̂CV respectively. 
Equations (2.15) and (2.16) clarify that a linear fit for LVADV  as in equation (2.14) might 
not necessarily provide the best fit capturing all possible data points. A fit combining (2.15) and 
(2.16) should be the actual fit L̂VADV . While running the regression model, the cubic polynomial 
did provide better goodness of fit as compared to a linear model, as shown in Table 2.9.  
Table 2.9: Comparisons of fits for LVADV  
Fit Order Linear Cubic 
Case 1(II) 2(II) 3(II) 4(II) 1(II) 2(II) 3(II) 4(II) 
SSE 3.09 1.66 0.60 0.01 0.01 ~10-4 0.00 0.00 
2R  0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 
Adjusted 2R  0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 
RMSE 0.21 0.17 0.99 0.02 0.01 0.01 0.01 0.01 
DFE 69 58 45 22 67 56 43 20 
 
Thus, the equation(2.17) represents the updated regression model (2.14), 
 3 21 2 3 4P̂VV z z zξ ξ ξ ξ= + + +  (2.17) 
To maintain the order consistency in terms of representing the volume of blood ejected 




Table 2.10 infers instead of the linear model in the equation (2.12) it makes for a better 
argument,for a cubic polynomial fit and  modified the fit as the following equation (2.18), 
 3 21 2 3 4ˆAVV z z zκ κ κ κ= + + +  (2.18) 
iξ and iκ  are the polynomial fit parameters for P̂VV  and ˆAVV  where 1, 2,3, 4i = . In 
Appendix E the fit parameters and the polynomial curves have been summarized in detail. 
Table 2.10: Comparisons of fits for AVV  
Fit Order Linear Cubic 
Case 1(II) 2(II) 3(II) 4(II) 1(II) 2(II) 3(II) 4(II) 
SSE 4.79 1.93 0.56 0.02 0.01 ~10-5 0.00 0.00 
2R  0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 
Adjusted 2R  0.99 0.99 0.99 1.00 1.00 1.00 1.00 1.00 
RMSE 0.26 0.18 0.11 0.03 0.01 0.01 0.01 0.03 
DFE 69 58 45 22 67 56 43 20 
2.4.3 Variation Associated with Contractility 
The other factor that influences the volume of blood ejected is the contractility of the heart. 
For a speed of 4000RPM, the volumes AVV , LVADV , PHV  and PCV  are simulated for maxE  values 




Figure 2.18: AVV  and LVADV  as a function of maxE  for a LVAD speed of 4,000 RPM 
 
Figure 2.19: PHV  and PCV  as a function of maxE  for a LVAD speed of 4,000 RPM 
As the contractility improves, meaning the condition of the heart is improving, the volume 
AVV increases. The heart can develop enough pressure to eject more blood through the aortic valve, 
despite the LVAD functioning at a constant speed. It is indicative of the fact that an improvement 
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in contractility directly impacts the action of the heart in the ejection of blood. AVV at an maxE  of 
1.0 is 21.29 ml and at 2.0 is 37.45 ml.  
In contrast, LVADV shows very marginal changes as contractility improves. The context in 
which this happens is explained more in Figure 2.19, which compares PHV  and PCV  for the same 
conditions. As the heart improves, the component PHV improves too, and the dynamics of the pump 
is such that PCV drops. PHV  at maxE of 1.0 is 13.57 ml and it increases to 15.52 ml at maxE of 2.0. At 
the same time, PCV drops from 17.86 ml at maxE of 1.0 to 14.94 ml at maxE of 2.0. The overall drop 
in PCV is higher than PHV which makes LVADV show a marginal change from 31.43 ml at maxE of 1.0 
to 30.46 ml when maxE is 2.0.  
For other speeds of the LVAD, a similar trend can be observed. The levels of contribution 
for the different volumes is dependent on the LVAD speed as discussed in section 2.4.1. The 
discussions on the speed and contractility proves that the volume of the blood ejected through 
either the aortic valve or the LVAD is dependent on both the speed and contractility. In section 
2.4.2, the analytical expression for the volume dependence on speed showed a cubic polynomial 
relationship. A similar relationship between volume and maxE will help to develop a complete 
picture of a predictive model for the volume using any given speed of LVAD or the contractility.  
2.4.4 Analytical Model for Volume using Contractility 
Similar to the regression fit in section 2.4.2, regression fits for ,  ,   and AV P PH PCV V V V  are 
established in this section with maxE as the functional term. The fits tried were a linear, 2nd order 
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and cubic fit. The goodness of fit for the three different fits suggested that the cubic fit with respect 
to maxE provide the least SSE, the best 
2R  and adjusted 2R and the smallest RMSE.  
The general fit function is, 
 3 21 2 3 4V p v p v p v p= + + +

 (2.19) 
Where, ip  for 1, 2,3, 4i = is the polynomial fit parameters, and v is the normalized value 
of maxE  around the mean of the range, 1.25 and a standard deviation of 0.57 for the range of maxE  
between 0.5 and 2.5. The parameters for each of the volumes alongwith the plots are in Appendix 
E. 
2.5 Analytical Model of Volumes as a Function of LVAD Speed and Contractility 
In section 2.3, an analytical regression model for the different volumes of blood ejected in 
a cardiac cycle was introduced. The volume is a function of a cubic polynomial concerning both 
speed of the LVAD and maxE . In this section, a 3D surface plot of a generic volume function 
concerning both speed of the LVAD and maxE will be looked into seeing if it can express the 
volume of blood ejected during a cardiac cycle as a composite function of both the concerning 
variables.  
The argument for the order of dependence of either of the variables has been established, 
meaning that in order to find the fit for the volume of blood ejected, ifdefined as _x̂ calcV , where x 
represents the pathway, then the form of this volume will be as,  
 ( ) [ ] [ ]3 3_ max maxˆ , , & 0.5,2.5x calc a bV f E Eω ω ω ω= ∀ ∈ ∈  (2.20) 
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 For consideration, _ˆAV calcV  is a surface that is in Figure 2.20, with the LVAD operating 
between 2,000 and 6,000 RPM which take up the range in(2.20). The speed range is such that the 
aortic valve is open for all speeds of the LVAD at the lowest value of the range of maxE , which 
covers Case 3(II). The dotted lines are the actual simulated AVV  values from (equation) for the 
different maxE values for the different speeds of the LVAD. These values are distinct depending 
upon the speed and maxE , and hence they appear as distinct dots. The colored surface is the 
regression fit according to (2.20), which provides a smooth continuous surface. The surface 
represents, _ˆAV calcV . 
 
Figure 2.20: Surface plot of _ˆAV calcV  as a function of Speed of LVAD and Emax. 
In terms of writing a function for this surface, the regression fit follows a polynomial 






















 2 2 3 2 2 3_ 1 1 2 1 2 3 2 3 3ˆAV calcV c a z b e a z c ze b e a z c z e c ze b e= + + + + + + + + +  (2.21) 
The regression parameters that make the equation (2.21) which characterize the surface 
shown in Figure 2.20 along with the goodness of fit are in Appendix E. The fit does not capture 
all the possible values of VAV, especially at the operating speeds when VAV = 0. It is indicative of 
the fact that there is a discontinuity in the possible fit region and that a surface would not be able 
to fully capture this without some errors in those regions. The same phenomenon is seen the fit 
shown in Figure 2.21, volume of blood ejected through the pump, and these errors are reflected in 
the SSE and RMSE values as listed in Appendix E.  
The functional form of this surface is pretty similar to the one in (2.21). The value of the 
coefficients are going to define the final function and using regression; they are found to be as in 
Appendix E. 
2 2 3 2 2 3
_ 1 1 2 1 2 3 2 3 3P̂V calcV c a z b e a z c ze b e a z c z e c ze b e= + + + + + + + + +  (2.22) 
 



















2.6 Characterization of Volume of Blood during Filling 
In the filling phase, the blood from the atrium flows into the ventricle through the mitral 
valve or the bicuspid valve. The pressure difference between the Left Atrium and the Left Ventricle 
govern the opening and closing of the mitral valve. The flow of blood through this pressure 
gradient is characterized by the resistance to flow of the fluid in the blood vessel of transport, 
which happens to be the mitral valve. Thus, the mitral valve flow MQ is expressed as,  
 
( ) ( )( )MV
M
LAP t LVP tQ t
R
−
=  (2.23) 
where ( )LAP t  is the Left Atrial Pressure, ( )LVP t  is the Left Ventricular Pressure and MR  is the 
Mitral Valve Resistance. Figure 2.22 shows the plot of the blood flow through the mitral valve for 
the different heart failure conditions. 
 
Figure 2.22: Flow through mitral valve over a cardiac cycle. 
The filling volume ( MVV  in ml)is calculated during the filling interval [ , ]c dt t  as,  






















m a x  = 0.75
E m a x  = 0.5
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V Q t dt= ∫  (2.24) 
The blood flowing in through the mitral valve fills the ventricle before the relaxation phase 
and subsequently is ejected out from the ventricle into the various vessels through the aortic valve, 
which is the cardiac output. Figure 2.23 plots the different volume of blood flowing through the 
mitral valve for the different cases described earlier when the LVAD is operating between speeds 









Figure 2.23: Volume of blood ejected through the mitral valve in a cardiac cycle as function of speed for (a) Case 
1(II), (b) Case 2(II), (c) Case 3(II) and (d) Case 4(II). 





















































2.7 Left Ventricular Volume 
The relationship between instantaneous volume and instantaneous pressure of the left 
ventricle, namely the elastance of the ventricle E(t), the expression for which is shown in (1.2) are 
discussed in [49, 50]. To calculate the left ventricular volume, from the model,(1.2) is rearranged 
since the model does not give LVV directly. The expression to find LVV(t) is as follows, 
 ( )( )
( )d
LVP tLVV t V
E t
= +  (2.25) 
As with other volumes, the left ventricular volume does show variation with the speed of 
the LVAD. In Figure 2.24, for Case 3(II), the left ventricular volume curve for speeds, 2,000, 
4,000, 6,000 and 8,000 RPMs are plotted for a cardiac cycle. The interesting point that can be 
noted is that the volume at the beginning of the cardiac cycle, a measure of the preload, is altered 
with speed. Also, the four phases of the cardiac cycle are modified due to the continuous unloading 
of the ventricle by the LVAD. As the speed increases, there is a region in which when the aortic 
valve opens, the profiles of the LVV curve merge and it can be seen for speeds between 2,000 to 
6,000 RPM. When the speed is 8,000 RPM, a speed when the aortic valve is permanently closed, 
the LVV curve is disjointed from the rest of the curves.  
In Figure 2.25, the variation of LVV curve with respect to the value of contractility is 
shown. The indication is that as the contractility increases with the LVAD running at a fixed speed, 
there is more ejection which is shown both in the volume of blood at the beginning of the cardiac 
cycle and also the change in volume during the ejection phase. This is due to the fact that the heart 
is able to pump more blood or act against the pressures added to the flow by the presence of the 
LVAD pump.  
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Due to the presence of the LVAD, the shape of the LVV curve does change from the curves 
produced in literature, shown in Figure 1.3. A detailed discussion of how the unloading due to the 
cfLVADs affects the LVV curve is taken up in Chapter 3. Two of the possible methods of 
evaluating the left ventricular volume using ultrasound and two-dimensional echocardiographs are 
shown in [108, 109].  
 
Figure 2.24: Left Ventricular Volume curves over a cardiac cycle for different speeds for Case 3(II). 
 
Figure 2.25: Left Ventricular Volume curves with LVAD 



















































The chapter discussed the various volumes of blood that are involved in each step of the 
cardiac cycle. The various volumes are discussed along with the formula of how to evaluate them 
using the blood flow curves. Also, the comparison of how the blood flows through the aortic valve 
and the LVAD as a function of speed and contractility were elaboraterd. The flow through LVAD 
was further split as the flow is influenced by the heart and also the impeller separately. An 
analytical view of each of the volumes was introduced using curve fitting, which might help in 
using such models for developing control of the pump. Finally, the left ventricular volume curve 
is defined, which is used for further discussion in the next chapter which takes up a new modified 
definition of ejection fraction. 
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CHAPTER 3  
LVAD AORTIC VALVE EJECTION FRACTION 
This chapter has been previously published in the journal, “American Journal of 
Cardiovascular and Thoracic Surgery”[110] and is reproduced and rephrased here according to the 
dissertation requirements under the licensing terms of Symbiosis Online Publishing and Open 
Access by Symbiosis under a Creative Commons Attribution 4.0 Unported License.  (Appendix 
“Z”contains the copy of the license). 
3.1 Introduction 
Cardiac contractility[111-116] is the intrinsic ability of the heart muscle to generate a force 
for the left ventricle (just considered in the dissertation) to contract and pump blood into the 
circulatory system. A reduction in contractility without compensatory changes in other vascular 
physiologies results in reduced cardiac output, which in turn causes downstream organ dysfunction 
leading to symptoms of heart failure. Ejection Fraction (EF) is a measure of the ability of the left 
ventricle to pump blood through the aortic valve, thus acting as a surrogate for the effects of 
cellular contractility, which is typically not easily measured.  EF is defined as   
SVEF= 100
LVEDV
×                        (3.1) 
where SV = LVEDV - LVESV is the stroke volume, LVEDVis the left ventricular end-
diastolic volume and LVESV is the left ventricular end-systolic volume.  The numerator in (3.1) 
corresponds to the volume of blood ejected through the aortic valve, and the denominator 
corresponds to the volume of blood available in the ventricle before ejection. Generally, EF in the 
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range of 55% and 75% is considered normal while declining EF values less than 50% indicates 
progressive heart failure.  Measuring EF is an important factor in determining how well the heart 
is pumping blood and in diagnosing and tracking heart failure. 
For patients supported with an LVAD, the above definition of EF remains an important 
metric in the assessment of their health condition[28]. LVADs are typically used as a bridge-to-
transplantation or destination-therapy. These can also be used as a bridge-to-recovery for a small 
subset of patients whose heart muscles have the potential to recover with the assistance of an LVAD 
[35, 117]. An important challenge for these patients is in assessing whether the left ventricle is 
regaining its ability to pump while supported by the LVAD.  
Recent studies [21, 118] have identified LVAD parameters to assess contractility of the 
heart. The measurement of cardiac performance as an assessment of heart contractility [119-122] 
has also been studied extensively. For patients without an LVAD, one standard measure to assess 
contractility is EF as defined in (3.1) [123, 124].  The numerator and denominator of (3.1) can be 
determined using the left ventricular volume (LVV) curve. However, for LVAD patients the left 
ventricle is not sufficiently preloaded due to the flow in the LVAD, causing a change in the shape 
of the LVV curve.  Any measure of EF with an LVAD implanted will consequently reflect the 
combined ability of both the heart and the LVAD to pump blood, hence not providing an accurate 
measure of cardiac performance. Therefore, a new index that takes into account the presence of the 
LVAD and gauges the sole ability of the heart to pump blood through the aortic valve despite the 
alteration in preload and afterload may be beneficial. When measured periodically, this index 




In this chapter, we propose a definition for this EF index, which we will refer to as the 
Aortic Valve Ejection Fraction (or AVEF). We investigate the feasibility of using AVEF, in 
comparison to EF, to monitor improvements in heart contractility that might occur while the 
LVAD is implanted. The lack of availability of animal or human heart contractility and LVAD 
hemodynamic data currently limits our ability to test AVEF on in-vivo data.  As a proof of concept, 
we utilize a standard validated left ventricle-LVAD mathematical model based on a generic axial 
continuous flow rotary pump, as introduced in Chapter 1. 
3.2 Definition and Characterization of AVEF 
 
Figure 3.1: Plot of LVV for a Patient without LVAD (blue) and with LVAD (brown) over one cardiac cycle. The 
times ta and tb represent the beginning and end of the ejection phase and tc represents the beginning of the filling phase.  
Variables with prime notation correspond to the patient with LVAD. 
In the presence of a continuous flow LVAD, the pump continuously unloads the left 
ventricle, while blood flows through the aortic valve only during the ejection phase of the cardiac 
cycle.  Figure 3.1 shows two typical LVV curves for the same patient with congestive heart failure 











































running at 4,000 RPM. For the patient without LVAD, the numerator of EF in (3.1) corresponds 
to the difference between the volumes at points D and C (or A and B), while the denominator 
corresponds to the volume at point D.   
 If the standard EF (3.1) is used for an LVAD patient (as is currently the practice), then 
points D’ and C’ are used instead of D and C in calculating the numerator and denominator of 
(3.1).  The resulting measure of EF will no longer reflect the ability of the heart to pump through 
the aortic valve, but instead it will now reflect the combined ability of both, heart and LVAD, to 
pump into the circulatory system. 
 Due to the continuous flow through the LVAD, the contraction and relaxation phases are 
not isovolumic and hence are difficult to distinguish on the LVV for the ventricle with LVAD. 
The difference between the volumes at points A’ and B’ represents the sum of blood ejected 
through the aortic valve and withdrawn by the LVAD, and points C’ and D’ represent the 
beginning and end of the filling phase. Thus, in order to account for the effect of the LVAD on 
LVV, instead of considering the end diastolic and systolic volumes, the denominator in the new 
definition should be the volume of blood available in the ventricle immediately before ejection. 
Thus, this dissertation defines the Aortic Valve Ejection Fraction, AVEF, as: 
 AVVAVEF= 100
LVVBE
×  (3.2) 
where VAV is the volume of blood ejected only through the aortic valve and LVVBE is the left 
ventricular volume immediately before the beginning of ejection. In Figure 3.1, VAV is the 
difference in volume between points A’ and B’ adjusted by the amount of blood withdrawn by the 
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LVAD and LVVBE corresponds to the volume at A’ which is the blood volume in the ventricle 
immediately at the time when the aortic valve opens.   
Unlike EF, where the numerator and denominator can be easily determined from the LVV 
curve, the numerator and denominator of AVEF cannot be easily determined from the LVV curve 
because points A’ and B’ (the end of diastole and systole) are not easily identifiable on the curve.  
To be able to identify these points accurately, the effect of the pump needs to be removed from the 
LVV with LVAD. Figure 3.2 shows a plot of LVADV , the volume of blood withdrawn from the left 
ventricle by the LVAD during the same cardiac cycle, and Figure 3.3 shows the LVV plot of Figure 
3.1 adjusted by removing LVADV . 
 





















Figure 3.3: Plot of LVV for a Patient with LVAD after the effect of the LVAD flow is removed. 
With this adjustment, the beginning and end of the ejection phase become easily 
identifiable as point A’, the point at which LVV starts decreasing and point B’ when LVV becomes 
constant again. Thus, points A’ and B’ correspond to the instants of the opening and closing of the 
aortic valve as shown in Figure 3.1. Points B’ in Figures 3.1 and 3.3 do not correspond, due to the 
volume of blood that was withdrawn by the pump while the aortic valve was open between ta’ and 
tb’ (13.4 ml in this case). Additionally, point C’ in Figure 3.3 represents the beginning of the filling 
phase, thus identifying the relaxation phase. Removing the effects of the pump alters the LVV 
curve in the filling phase, as can be seen in Figure 3.3.  This will not affect the AVEF index since 
the filling phase does not play a role during ejection. Thus, from the LVV plot shown in Figure 
3.3, VAV = 21ml represents the difference in volume between points A’ and B’, and LVVBE = 
119ml is the corresponding volume at point A’. This yields a calculated AVEF = (21/119) x 
100=18%.  For this patient, calculating EFusing points D’ and C’ yields EF = ((124-79)/124) x 






















C as EF = ((130 – 83)/130) x 100 = 36%. For the patient with LVAD, the difference between 
AVEF=18% and EF=36% is because in addition to the flow through the aortic valve, EF includes 
blood flow through the LVAD while AVEF does not. It should be pointed out that for a patient 
without LVAD, AVEF will be the same as EF. 
3.3 Characterization of AVEF and EF as a Function of LVAD Speed 
Contractility of the heart muscle is generally measured in terms of its elastance, which 
represents the change in pressure per unit volume[49, 52]. An important measure of the elastance 
function is its maximum value, Emax, which usually occurs within the ejection cycle.  A correlation 
between Emax and EF to establish the degrees of CHF as defined to follow the New York Heart 
Association (NYHA)[53, 54] classification is noted in Table 3.1. Figure 3.1 was obtained using 
the model for a CHF patient with Emax = 1.0 mmHg/mlwithout LVAD and with an LVAD set at 
4,000 RPM (LVAD flow rate of 2.35 L/min).  
Table 3.1: Extension of Cases of Heart Failure Conditions to correlate NYHA Class and EF 
Case Condition of Heart EF(%) Emax (mmHg/ml) NYHA Class 
1 Normal 50 – 70 >2.0 - 
2 Mild Dysfunction 40 – 49 1.25 – 2.0 I 
3 Moderate Dysfunction 30 – 39 0.8 – 1.25 II 
4 Severe Dysfunction <30 <0.8 III – IV 
 
An important distinction between EF and AVEF is that AVEF depends on the LVAD 
rotational speed[125]. Thus, in order to test the effectiveness of AVEF we examined the LVV 
curve with and without LVAD data for different degrees of CHF and different rotational speeds of 
the LVAD. The calculation of AVEF for a range of speeds from 2,000 to 10,000 RPM for an 
LVAD patient with Emax = 1.0 mmHg/ml (Case 3(II)) by simulating the model.  The resulting plot, 
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Figure 3.4 shows that AVEF decreases with increasing speed and confirms that the contribution 
of the left ventricle to the total flow decreases as the contribution of the LVAD increases. At 6,700 
RPM, the aortic valve closes permanently and AVEF = 0% reflecting the fact that the total flow at 
this and larger speeds are solely through the LVAD with no flow through the aortic valve. The 
specific case that was discussed earlier in the LVV of Figure 3.1 at 4,000 RPM is indicated in 
Figure 3.4 showing an AVEF =18%. 
 
Figure 3.4: AVEF versus LVAD Rotational Speed for Case 3(II). 
Table 3.2 provides a comparison of AVEF and EF for the same LVAD patient considered 
in Figure 3.1 whose unassisted EF is 36%.  This table shows that AVEF decreases rapidly while 
EF changes very little with increasing speed up to a speed of 6,700 RPM when the aortic valve 
closes. For speed larger than 6,700 RPM, AVEF= 0 while EF increases rapidly and reaches a value 
of 49%  at a speed 10,000 RPM. The increased distortion in the EF values at large LVAD speeds, 
makes EF an unreliable index for estimating the correct patient’s ejection fraction when the aortic 
valve is closed at large LVAD speeds. 



















Table 3.2: Comparison of AVEF and EF at Different LVAD Speeds for an LVAD Patient Whose Unassisted EF is 
36% 
Speed (RPM) AVEF (%) EF (%) 
2,000 28 37 
3,000 23 36 
4,000 18 36 
5,000 12 35 
6,000 5 35 
7,000 0 35 
8,000 0 39 
9,000 0 44 
10,000 0 49 
 
 
Figure 3.5: AVEF versus LVAD Rotational Speed for Case 4(II). 
Extending the definition for the other cases, Figure 3.5 shows the AVEF versus speed for 
Case 4(II). The unassisted EF for this particular case when Emax = 0.5 mmHg/ml is 20.94% and 
AVEF = 0 at 4,400 RPM. Similarly, Figure 3.6 is the plot for Case 2(II), with unassisted EF for 
this case (Emax = 1.5 mmHg/ml), is 47.66% and AVEF = 0 at 8,000 RPM. For Case 1(II), Figure 
3.7 shows the plot of AVEF versus rotational speed of the LVAD where the unassisted EF for this 
case being 55.27% and AVEF = 0 at 8,900 RPM.  



















Figure 3.6: AVEF versus LVAD Rotational Speed for Case 2(II). 
 
Figure 3.7: AVEF versus LVAD Rotational Speed for Case 1(II). 
3.4 Sensitivity of AVEF to Changes in Heart Contractility 
As mentioned earlier,  one of the current practices is to rely on the EF index to monitor 
possible improvements in heart contractility for patients supported with LVAD [27, 28].  The 
question is; how does AVEF compare to EF in assessing improvements in heart contractility in 






































LVAD patients? While the absolute value of these indices may not be of much interest, it is their 
sensitivity to small changes in contractility that provides the necessary information about the 
condition of the heart in an LVAD patient.  In many cases, marginal improvements in heart 
contractility may be of interest and these can only be detected if the index can provide sufficient 
sensitivity to these changes to make the detection possible. 
 
Figure 3.8: AVEF versus Emax parametrized for speeds in the range 2,000 to 10,000 RPM. 
Since AVEF depends on the LVAD speed, its usefulness will be most effective if 
monitored at a specific speed setting.  This does not disadvantage AVEF since the current practice 
is to keep the speed setting fixed in outpatient LVAD control.  For a fixed speed setting, it is 
important to first assess if an increase in AVEF over a period of time can be attributed to an 
increase in contractility over the same period. Figure 3.8 shows plots of AVEF versus Emax for 
LVAD speeds in the range 2,000 to 10,000 RPM. As seen in the previous section, AVEF is equal 
to 0 when the aortic valve is permanently closed. Thus, an important property of AVEF is that its 
value does incorporate the status of the aortic valve at each speed setting. Furthermore, there are 



























no irregularities in the AVEF profile over the range of Emax. These plots show that at any fixed 
speed setting, there is a clear positive correlation between AVEF and Emax. 
Next, the study will examine the sensitivity of AVEF to variations in Emax at a fixed LVAD 
speed over a wide range of patient physiological conditions. The patient’s afterload is altered using 
the systemic vascular resistance RS. A value of RS=1.0 mmHg-s/ml was taken as the base value 
representing normal afterload. At a fixed LVAD speed of 4,000 RPM, Figure 3.7 shows a bar chart 
plot of AVEF for values of RSranging from 0.8 to 1.2 mmHg-s/ml.  For each value of afterload, 
Emax was increased from 0.5 to 2.5mmHg/ml.  This Figure illustrates how AVEF varies with 
afterload and heart contractility.  For a fixed afterload, AVEF increases with increasing Emax and 
for a fixed Emax, AVEF decreases with increasing afterload. Knowledge of the afterload, however, 
would still be required if the exact amount of increase in Emax is needed. As an illustration, at an 
afterload of RS= 1.0 a change in Emax from 1.0 to 1.5 (50% increase) yields a change in AVEF 
from 18 to 28 (a 56% increase). Similarly, for an Emax = 1.5, a change in SVRfrom 1.0 to 1.1 (10% 
increase) yields a change in AVEF from 28 to 26 (7% decrease). This high sensitivity of AVEF to 
changes in Emax for a wide range of physiological conditions is largely due to the fact that the flow 
through the aortic valve,which AVEF measures, carried with it a high percentage of information 
about contractility of the left ventricle. 
Figures 3.10 – 3.12 show similar plots of AVEF’s variation with afterload and contractility 
similar to Figure 3.9 for different speeds of LVAD. The speeds shown here are 2,000 RPM, 6,000 
RPM and 8,000 RPM. AVEF is higher for each contractility at a speed of 2,000 RPM which 
indicates that at this speed, the heart does provide more blood as compared to the LVAD. At 8,000 
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RPM, for Emax<1.0, AVEF is non existent which indicates that the aortic valve is shut and hence 
only the LVAD ejects at this speed.   
 
Figure 3.9: AVEF versus RS(afterload) for different CHF conditions characterized by Emax for speed 4,000 RPM. 
 
Figure 3.10: AVEF versus RS(afterload) for different CHF conditions characterized by Emax for speed 2,000 RPM. 
































































Figure 3.11: AVEF versus RS(afterload) for different CHF conditions characterized by Emax for speed 6,000 RPM. 
 
Figure 3.12: AVEF versus RS(afterload) for different CHF conditions characterized by Emax for speed 8,000 RPM. 
3.5 Why is AVEF more reliable than EF to correlate with contractility? 
In order to appreciate the differences in sensitivity and characteristics between AVEF and 
EF, the results of Figures 3.8 and 3.9 were reproduced when EF is used instead of AVEF for the 
same LVAD patient.  Figures 3.13 and 3.14 – 3.17 show plots of EF versus Emax for the same range 































































of LVAD speeds and afterloads considered for AVEF in Figures 3.8 and 3.9.  A close examination 
of Figure 3.13 shows a much more disorganized behavior of EF versus speed (this is also apparent 
in Table 3.2) than Figure 3.8. Additionally, the behavior for Emax< 1.5 is completely different than 
when Emax> 1.5.  Figure 3.14 shows that EF is less sensitive than AVEF to variations in heart 
contractility. For the same illustration considered above in the case of AVEF, the 50% increase in 
Emax (1.0 to 1.5) resulted in an increase in EF from 36 to 48 (33% increase) and the 10% increase 
in SVR resulted in a decrease in EF from 48 to 46 (4% decrease). 
 
Figure 3.13: EF versus Emax parametrized for speeds in the range 2,000 to 10,000 RPM. 
The value of EF for different afterloads for any given contractility show very minimal 
change when the speed is changed as shown in Figures 3.14 – 3.17. For a case of RS= 1.0 and Emax 
= 1.0, when speed is 4,000 RPM, EF = 36% as seen from Table 3.2. Now when speed is 2,000 
RPM, from Figure 3.15, EF is 37%; when speed is 6,000 RPM, from Figure 3.16, EF is 35% and 
finally, when speed is 8,000 RPM, from Figure 3.17, EF is 39%. It is interesting to note that EF 
value reduces a bit as speed is between 2,000 RPM and 6,000 RPM, whereas it increases a little 

























when speed is 8,000 RPM. As noted at this speed, the aortic valve is shut and hence the increase 
in EF value. For the change of EF with speed for the same afterload and contractility, EF does not 
provide the same information that AVEF does or is as sensitive as AVEF, and even with afterload 
changes, the sensitivity is low.  
 
Figure 3.14: EF versus RS(afterload) for different CHF conditions characterized by Emax for speed 4,000 RPM. 
 
Figure 3.15: EF versus RS(afterload) for different CHF conditions characterized by Emax for speed 2,000 RPM. 




























































Figure 3.16: EF versus RS(afterload) for different CHF conditions characterized by Emax for speed 6,000 RPM. 
 
Figure 3.17: EF versus RS(afterload) for different CHF conditions characterized by Emax for speed 8,000 RPM. 
Table 3.3 provides a comparison of the sensitivities of AVEF and EF due to changes in 
Emax for a patient with an LVAD speed set at 4,000 RPM and average afterload (RS=1).  As an 
illustration, a 10% improvement in Emax results in 13.20% increase in AVEF and a 7.52% increase 
in EF.  In general,  research indicates that for a wide range of Emax values, LVAD speeds, and 
afterloads, AVEF is approximately twice as sensitive to changes in Emax than EF.  It should be 





























































pointed out that for the range of Emax from 0.5 to 2.5, values of AVEF are consistently lower than 
values of EF as can be seen when the plot of Figure 3.5 is compared to Figure 3.7.  This difference 
corresponds to the positive bias introduced in EF due to the flow in the LVAD.  As noted in Table 
3.2, this bias becomes larger at higher speeds. One of the main disadvantages of this bias is that it 
amplifies the effects of measurement errors.  
Table 3.3: Sensitivity of AVEF and EF to Changes in Emax 
∆Emax ∆AVEF ∆EF 
1% 1.40% 0.77% 
2% 2.74% 1.55% 
5% 6.77% 3.82% 
10% 13.20% 7.52% 
15% 19.45% 11.08% 
20% 25.44% 14.50% 
25% 31.22% 17.81% 
 
Finally, it may be interesting to examine the difference between AVEF and EF from a 
hemodynamic perspective. One of the main problems of using EF in LVAD patients is that the 
linearity of the ESPVR, which is characteristic in patients without LVAD, is now altered due to 
the presence of the LVAD. According to the literature [119], the LVAD alters the linearity of 
ESPVS which affects the linear relationship between the left ventricular volume (LVV) and left 
ventricular pressure (LVP) whose ratio corresponds to the ventricular elastance. Thus, to get a true 
measure of elastance, the linear relationship between LVV and LVP, and hence the linearity in the 
ESPVR, needs to be restored in LVAD patients. This restoration is accomplished by removing the 
LVAD flow from the LVV curve as is done in AVEF.  
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3.6 Frank–Starling Curves based Map for Correlating AVEF and Contractility 
In this section, we establish a one–to–one relationship between change in AVEF and Emax, 
and examine the corresponding Frank–Starling curve using components of AVEF as defined in 
(3.2). The Frank–Starling curve establishes a relationship between SV and end diastolic volume 
[126, 127]. This curve is used to monitor improvements in cardiac function in patients with CHF 
[128]. For patients with a continuous flow LVAD, SV is VAV, and the end-diastolic volume is 
LVVBE. A heart with improving contractility if supported with an LVAD should show an increase 
in VAV and a decrease in LVVBE resulting in increasing AVEF. 
Figure 3.9 shows plots of VAV versus LVVBE with varying contractility (Emax), afterload 
(RS) and LVAD speed (that does not cause the aortic valve to close permanently). Each colored 
group refers to the family of Frank–Starling plots for the same Emax value. The contractility 
increases from the family of curves shown in green to the family of curves shown in blue. Within 
the family of curves, the speed of LVAD that each curve represents is specified next to the curves 
in green, and the curves are indicated by a different curve pattern. In each of these curves, the 
value of RSchanges, as indicated. Operating points of interest are combined together by solid black 
lines, representing the same afterload conditions, same LVAD speed, and different Emax values. 
All operating points shown in the plot represent an afterload identified by an RS= 1.0. 
This map confirms that an increase in AVEF may be due to an increase in Emax. For 
example, for a specific LVAD speed (say 4,000 RPM), as one moves from point c3 to point c1, 
AVEF increases (VAV increases while LVVBE decreases) corresponding to increasing Emax. The 
same can be observed for the other sets of operating points as marked on the map. Such an analysis 
is possible to be made when any of the three parameters considered is changing. To know for 
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certain that an increase in AVEF is only due to Emax, further analysis of the model has to be carried 
out which is beyond the scope of this project. An interesting observation that arises out of this 
generic map and which would be the next step in our research is to consider other scenarios such 
as changing speed (ramp test) and constant monitoring (outpatient setting). 
 
Figure 3.18: Generic Map of Frank – Starling Curves (VAV versus LVVBE) for different Emax with changing speeds 
and RS. 
3.7 Analytic Formulation of AVEF with Speed and Contractility 
As discussed in Chapter 2, where the volume of blood ejected through the aortic valve as 
well as through the LVAD was analytically fit to curves and functions deduced using regression, 
AVEF can be handled the same way. It is obvious from the definition of AVEF, the numerator is 
as discussed from Chapter 2, VAV can be fit into a cubic polynomial in both speed and contractility. 
Doing a similar analysis, it should be possible to fit AVEF into a cubic polynomial first with 
respect to speed and further with respect to contractility. As AVEF is a ratio, and with the 














































numerator fit with a cubic polynomial, it might be appropriate to try and fit the denominator 
similarly. Yet from a clinical perspective, understanding LVVBE might not be very useful. 
Whereas as discussed in Sections 3.3 and 3.4, AVEF is directly shown to be dependent on speed 
and contractility. Hence, this dissertation, using the model,is able to fit AVEF as a function of 
speed and contractility directly instead of using VAV and LVVBE separately. Similar to equation 
(2.18), we can deduce a cubic polynomial as,  
 3 21 2 3 4AVEF z z zχ χ χ χ
∧
= + + +  (3.3) 
Where, iχ  is the polynomial fit parameter and z  is the normalized speed about the mean 
and standard deviation as discussed in Chapter 2. These parameters for the different cases are 
presented in Appendix F. Similar to (2.19), using the same assignment of variable ν , AVEF can 
be fit using a polynomial as and with the parameters summarized in Appendix E,  
 3 21 2 3 4AVEF v v vϕ ϕ ϕ ϕ
∧
= + + +  (3.4) 
Combining both speed and contractility it is possible to visualize a surface for AVEF 
calculation by providing speed and contractility. Primarily, the SVR (RS) is assumed to be known 
and a constant for equation (3.5) to be used. It is hard to visualize a 4 dimensional function and 
hence it would be ideal to combine the surface that can be obtained using (3.5) and the map shown 
in Figure 3.18. Essentially, the family of such surfaces can be used to calculate AVEF for purposes 
of treatment. To illustrate, Figure 3.19 shows the surface obtained for AVEF as a function of speed 
and contractility for a certain value of RS (Fit Parameters and Goodness of Fit in Appendix E) and 
Figure 3.20 shows a plot of the family of surfaces that is possible to generate for different values 
of RS.  
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Figure 3.19: Surface plot of AVEF as a function of Speed and Emax. 
 





















































In terms of the AVEF in Figure 3.19, the AVEF values at higher speeds go to 0 and the 
surface does not capture these points. They are the extreme points and are pretty much like a 
extremums to the surface perfectly capturing these values. These points at higher operational 
speeds are the reason for the errors in the surface to the simulation values and surface would give 
unstable values at these speeds.  
3.8 Summary 
To summarize, from a clinical perspective, the strong positive correlation between AVEF 
and Emax is very important in that it does suggest that periodic measurements of this index in 
bridge-to-recovery patients, may provide crucial information in assessing the recovery condition 




CHAPTER 4  
SHARING AND COOPERATION AMONGST HEART AND LVAD 
The development of LVAD technology, particularly the continuous flow LVADs 
(cfLVADs), has resulted in management of more number of outpatients with continuous 
mechanical support [27, 28, 129]. LVADs, primary function of which is to restore healthy organ 
functions leading to meaningful rehabilitation, are typically used to enhance the quality of life of 
heart failure patients [130, 131]. The emphasis on the management of patients implanted with 
continuous-flow LVADs has become a focal point [132].  
An increase in perfusion and reduction in pulmonary pressures, apart from the 
enhancement of quality of life, is observed. In terms of the quality of life, patients might also be 
able to have a better response to change in activity levels from the pre LVAD conditions [133-
135]. Although each patient can respond differently to LVADs, studies report that significant 
improvements in NYHA functional class from NYHA class before LVAD implant from IIIb – IV 
to I – II after about one year of implantation [136, 137]. Cardiac rehabilitation can help restore and 
improve aerobic work capacity, physical strength, mobility after LVAD implantation, as shown in 
the study by [138]. 
Studies conducted to study the exercise capacity changes after the implantation of a 
cfLVAD, which, although limited, have been increasing in recent years [129, 132, 135, 138-140]. 
It is important to note that proper exercise training for patients with LVADs [141-143] will be not 
only safe for the patient but also be useful to show improvements in exercise capacity and quality 
of life scores, and [141] discusses that with at least six weeks of training these improvements can 
be visualized. These studies come with certain limitations, one among which is the lack of 
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substantial pre-LVAD data for comparison. Hence the effect LVADs have on the capacities of the 
patients is difficult to understand [135]. Another factor that limits the analysis is the difficulty in 
comparing the data of patients undergoing different types of therapy using cfLVADs. Various 
exercise and functional capacities have been reported, sometimes not inclusive of some 
demographics, showing that the way a patient responds to the treatments and exercise training 
might differ between individuals.  
 Currently, commercially available cfLVADs are operated at fixed speeds, regardless of 
the patient activity level [132]. In terms of the latest studies, [132, 140] studied the impact of 
keeping a fixed speed across varied activity levels. The logical approach behind the study has been 
the linear relationship between pump speed and pump flow. Both studies conclude that the increase 
in pump flow at a fixed speed is minimal in comparison to the normal physiological response.  
In this chapter, a summary of results from previous studies, in brief, explains the motivation 
of the study done in this dissertation. The methodology, the different cases that are covered, as 
well as the observation, will be further discussed.  
4.1 Background Study and Motivation 
In the study by Lai et al., on the impact of pump speed on hemodynamics with exercise 
[132], the hypothesis that a higher pump speed during graded exercise results in an improved 
invasively measured central hemodynamics was tested. It was ensured that the patients chosen 
showed that a sufficient increment in pump speed is possible without any inducement of suction. 
The parameters measured included heart rate (HR) using ECG, mean arterial pressure (MAP) non-
invasively using Doppler – guided sphygmomanometery, the left ventricle dimensions at end-
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systole and end-diastole measured by transthoracic echocardiography, apart from right heart and 
central hemodynamics such as right atrial pressure (RAP), mean pulmonary arterial pressure 
(MPAP), and pulmonary capillary wedge pressure (PCWP), which were done invasively using a 
catheter. The LVAD parameters such as speed and power were recorded apart from estimating 
flow from the LVAD monitor. These parameters were recorded for every change in speed and 
exercise.  
The parameters mentioned were recorded with the patient at rest, and kept as baseline 
values. With the patient still at rest, the pump speed was increased in equal steps every 2 minutes. 
The increase in speed was stopped after a fixed number of steps above baseline speed, or in the 
event of suction. After establishing a safe working maximum, the pump speed was reduced back 
to baseline in the same step values as the increase till the baseline speed giving sufficient time to 
allow for re-equilibration before the exercise protocol was carried out. A similar step-wise 
increment of exercise levels was followed as the exercise protocol, with workload increasing after 
a fixed time interval.  
The main findings from the study highlighted that increased pump speed results in greater 
pump flow and lower PCWP than at baseline speed, which indicated a limited increase in left sided 
filling pressures, while both the left and right heart pressures remained elevated. It was also noted 
that mixed venous oxygen saturation did not improve with maximum speed despite an increase in 
the pump flow, which also meant an inadequate cardiac output.  
Pump flow through a cfLVAD is driven by the impeller speed and the pressure gradient 
across the pump. The pump pressure head is inversely related to the pump flow [30]. A 
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spontaneous increase in the pump flow from rest to exercise is largely due to the increase in venous 
return and preload [144-149].  
A study by Gross et al. [140], hypothesized that at a fixed speed, despite the increase in 
pump flow, the changes vary minimally between different levels of exercise. In this study, 
parameters such as mean LVAD output, aortic valve opening and heart rate were calculated for 
every cardiac cycle from the LVAD pump flow waveform. The study compares the LVAD 
responses to maximal bicycle exercise tests (MBET) and submaximal exercise, which comprise of 
a 6-min walk test and four exercise trainings comprising of interval bicycle ergometer training, 
walking, mobilization and strength training for the lower limbs. The study also observed that an 
increase in LVAD output at a fixed speed is due to a decrease in the pump head pressure. Apart 
from the factors mentioned by other studies for the decreasing pump head pressure as mentioned 
earlier, an increasing LV contractility and reducing afterload are also discussed as possible reasons.  
The results observed in this study suggested that an increase in the LVAD flow is moderate 
and similar for both maximal and submaximal exercises. Further on, the response of the supported 
heart was found to be proportional to the intensity of the exercise, whereas the pump flow response 
was found to be unchanged. This leaves the cardiovascular function to compensate further in the 
event of a change in the intensity of exercise from a submaximal level to maximal levels. The 
results of the study underline the importance of the ability of the LV to generate ejection through 
the aortic valve additional to the pump flow, therefore indicating that the aortic valve dynamics 
could be a sufficient predictor of exercise capacity. 
As discussed in previous chapters, the study points to the interaction between the supported 
heart and LVAD, especially when the AV is open as a competition. It is understood that the AV 
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opening limits the flow through the pump, as it alters the pump head pressure as shown in Chapter 
2. But, in terms of exercise the study by Gross et al., points out that as the ejection increases 
through the AV, at a fixed speed, with an increase in exercise levels, the concomitant increase in 
the pump flow expected is limited by the AV opening. Furthermore, it is pointed that remaining 
LV contractility during exercise associated with increased AV ejection results in increased 
afterload, leading to attenuation of the increase in LVAD output.   
The impact of maximum pump speed studied on exercise-induced changes in the 
hemodynamics is fundamental in assessing whether there is a possibility to achieve exercise 
augmentation in patients by having a pump control algorithm to vary the pump speed according to 
demand. Exercise changes the hemodynamics in such a way that it alters heart rate, SVR, LV 
loading, and aortic ejection, the discussions of which have been extensively covered in Chapter 2. 
As such, [132] notes that studying simultaneous intra-arterial pressure waveforms and pump 
function might help definitively understand the determinants required for dynamic pump control.  
Higher pump speeds may be able to provide a higher flow at more significant pump head 
pressures forms the rationale behind studying the possibility of adjusting the pump speed. These 
recent studies have certainly provided a great deal of motivation about how a fixed speed setting 
for an LVAD supports a patient in conditions of exercise. A mathematical model analysis, although 
it is not a replacement for animal or human data analysis, might provide the ability to explore 
further all the different parameters discussed in these studies to the degree that can help eventually 
attain a dynamic control of the LVAD pump. 
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4.2 Fractional Blood Flow 
Blood flow, when an LVAD is implanted, between the ventricle and the aorta, is split 
between a) the native circulation through the aortic valve and b), through the LVAD pump. This 
is shown in Figure 2.9 as Path 1 representing the flow through the aortic valve, and Path 2, the 
flow through the LVAD pump. It is well known in fluid dynamics that the flow between two points 
for a fluid is driven by the pressure difference between those two points. As such, the flow between 
the ventricle and the aorta is driven by the pressure difference between the ventricular pressure 
and the aortic pressure. In simple form, Figure 4.1 shows the net blood flow into the aorta as a 
summing function of volumes of blood flowing through both paths and the nature of the flow too.   
 Hemodynamics give the relationship between blood flow, pressure difference and the 
resistance. In the case of Path 1, this resistance refers to the aortic valve resistance, which is related 
in large part to the size of the valve opening.  
4.3 Heart and LVAD Sharing 
The primary purpose of the dissertation is to address the effectiveness of the assistance 
provided by the LVAD running at a fixed speed in combination with the cardiovascular system, to 




















healthy person. As a reference, the model is run to establish baseline data for a healthy person at 
different levels of activity, as defined in Table 4.1,  with no LVAD. The first step is to record the 
physiological parameters for a healthy person as baseline data. To simulate a healthy person, the 
5th order model without LVAD with Emax = 2.0 mmHg/ml is simulated for different activity levels.  
The volume of blood in ml ejected for every cardiac cycle or stroke volume, SV, through 
the aortic valve, the cardiac output in ml/min, CO, and the ejection fraction in %, EF are noted for 
these levels of activity for a healthy patient.  
Table 4.1: Defining Activity Level and Listing Cardiac Parameters for a Healthy Person 
RS HR Activity Level SV CO EF 
1.2 60 Resting (RG) 66.59 3.99 56.36 
1.0 75 Light Movement (LM) 64.66 4.85 55.27 
0.8 90 Light Exercise (LE) 66.31 5.97 56.13 
0.6 105 Exercise (EX) 72.19 7.58 58.66 
0.5 120 Maximal Exercise (ME) 74.28 8.91 59.44 
 
Ideally, for a patient with heart failure, LVADs should assist in meeting the demands of 
the patient, allowing the patient to be active and also enhance quality of life. The objective would 
be for a heart failure patient with LVAD assistance, at any level of activity, the total volume of 
blood that is supplied to the circulatory system would be close to the volume of blood that a healthy 
person achieves. A fractional analysis would help in comparing the data from a sick patient to a 
healthy person, and for this, a few fractions are defined.  
First, the fraction of total cardiac output (TCO), the sum of both the heart and the LVAD, 
to the cardiac output of a healthy person is defined as,  




V V HRV HRTCOF
CO SV HR SV HR
+
= = =  (4.1) 
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In equation (4.1), VT is the total volume of blood ejected by the cardiovascular-LVAD 
system, SV is the stroke volume of a healthy person, HR is the heart rate, VAV is the volume of 
blood ejected through the aortic valve in a patient with LVAD, and VLVAD is the volume of blood 
ejected through the LVAD. For a patient with Emax = 1.0, FTCO is calculated and plotted for different 
activity levels at speeds varying between 2,000 to 10,000 RPM, at intervals of 1,000 RPM.  
 
Figure 4.2: FTCO for different levels of activities and speeds for a patient with Emax = 1.0. 
 
At 2,000 RPM the total cardiac output for a heart patient is almost at the same level for 
different levels of activity. The value is close to 77% of the cardiac output of a healthy person. 
Clearly the heart and the LVAD together does not provide blood in every cardiac cycle 
equivalently to a healthy person. This shows that irrespective of the level of activity that a person 
is at, the speed of the LVAD at 2,000 RPM, which is a low speed, will not be sufficient unloading 
to supply blood to the person with heart failure.  




















Now in equation (4.1), FTCO,  can be further split into two components, one with the aortic 
valve and the other with LVAD. Reducing (4.1), we get two equations, which we define FAV, the 
fraction of blood ejected in a cardiac cycle by the heart through the aortic valve as compared to a 
healthy heart, equation (4.2) and FPV, the fraction of blood ejected in a cardiac cycle through the 

















Figure 4.3: FAV for different levels of activities and speeds for a patient with Emax = 1.0. 
Figure 4.2, shows the plot of FAV for the test cases considered in Figure 4.1. At a speed of 
2,000 RPM, FAV shows a variation from 52.83% at resting to 65.61% at maximal exercise. This 
means at a low speed, the heart ejects more blood as compared to the LVAD, meeting only a part 
of the blood necessary to satisfy the requirements as compared to a healthy person. It would be 





















ideal if the LVAD took over the reminder of the blood that needs to be supplied equivalent to a 
healthy person. Whereas, in the subsequent plot, at a speed of 2,000 RPM, FPV drops from 25.43% 
at resting to 11.51% at maximal exercise. The numbers indicate that the LVAD does more work 
at rest than when the person is more active, or in other words, the heart tends to assert itself in the 
cooperative play between the heart and LVAD. So at 2,000 RPM, when FTCO, is almost a constant 
across activity, as activity increases, the heart does more work thereby leaving the LVAD to do 
less at the same time of providing about 75% of the blood that a healthy person receives.  
 
Figure 4.4: FLVAD for different levels of activities and speeds for a patient with Emax = 1.0. 
 The plots show that as the speed of the LVAD increases, FTCO increases for all activity in 
comparison to the immediate lower speed. Table 4.2 represents the values of FAV, FLVAD and FTCO 
when the speed changes from 4,000 RPM to 5,000 RPM. FAV decreases from the immediate lower 
speed until a certain point where it becomes 0. FLVAD should increase given that the speed of the 
LVAD increases, which means more blood will flow through the LVAD.  
 





















Table 4.2: Summary of FAV, FPV, FTCO and AVEF for 2 speeds during Resting and Maximal Exercise 
 Resting Maximal Exercise 
4,000 RPM 5,000 RPM 4,000 RPM 5,000 RPM 
FAV 24.40% 10.31% 51.97% 44.55% 
FLVAD 58.76% 76.03% 27.65% 36.59% 
FTCO 83.27% 86.46% 79.65% 81.17% 
AVEF 13.91% 6.39% 29.17% 25.65% 
  
The take away from Table 4.2 is that at a higher level of activity, delivery of blood fraction 
is smaller as compared to rest. Meanwhile, the fraction of blood that is provided by the heart alone 
increases, indicating that the heart takes over in the event of increased activity from the LVAD. In 
the dance between the heart and the LVAD, the level of activity does determine the cooperative 
deliverance of blood by the two. The fraction shows the opposite trend as the speed increases as 
the activity level remains the same, FAV shows a decrease, while FLVAD increases enough to 
increase FTCO. In essence, FTCO is proportional to the speed of LVAD, whereas it is inversely 
proportional to the level of activity of the patient, which is similarly the case with FLVAD, and FAV 
shows an inverse effect comparatively. If the patient’s activity changes from resting to maximal 
exercise, and the speed also increases from 4,000 RPM to 5,000 RPM as in Table 4.2, then it can 
be seen that FTCO decreases a little from 83.27% to 81.17%, FLVAD decreases from 58.76% to 
36.59% and FAV increases from 24.40% to 44.55%.  
 The inference arrived is that the combined cardiovascular – LVAD system is not capable 
of providing sufficient blood to a patient in comparison to a healthy person when the activity of 
the person changes keeping the speed of the LVAD fixed, whereas if the speed of the LVAD 
changes then there is a possibility of providing the required sufficient blood. The next question 
that needs addressing is what level of speed can help achieve a sufficient blood supply.  
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4.3.1 Aortic Valve Dynamics and Response to Activity 
In order to achieve an equivalent supply of blood as compared to a healthy person, the 
requirement would be to have FTCO as close to 100% as possible. Going back to Figure 4.1, FTCO 
approaches 100% at 7,000 RPM for resting, slightly more than 8,000 RPM for light movement, 
between 9,000 and 10,000 RPM for light exercise, and greater than 10,000 RPM for exercise and 
maximal exercise. The question arises, what state do these speeds leave the aortic valve in, whether 
it is opening and closes usually, or shuts permanently.   
Table 4.3: Percentage of Aortic Valve Opening at the Speed when FTCO is 100% 
Level of Activity AVOP(%) at Speed When FTCO approaches 
100% 
Resting 0 
Light Movement 0 
Light Exercise 0 
Exercise 0 (FTCO = 94.25% at 10,000 RPM) 
Maximal Exercise 16.66 (FTCO = 90.45% at 10,000 RPM) 
 
A common thread that is observed from Table 4.3 is that when FTCO is close to 100%, all 
of the blood flows through the LVAD, which is AVOP, is 0%. It is indicative of the aortic valve 
is shut permanently. By the definition of FAV, it can be said FAV = 0% in all cases except maximal 
exercise. In these cases, FTCO = FLVAD. In the case of maximal exercise, FAV = 6.53%. Table 4.4 
summarizes the speed at which FAV = 0%, that is the speed of the LVAD that makes the aortic 
valve permanently shut down. Also, the corresponding value of FTCO at that speed is noted. For 
the case of Emax of 1.0, the aortic valve seems to permanently close when the value of FTCO 





Table 4.4: Summary of Speed when Aortic Valve Shuts down permanently and the corresponding FTCO 
Level of Activity Speed at FAV = 0% FTCO at Speed 
Resting 6,000 90.97% 
Light Movement 7,000 91.05% 
Light Exercise 8,000 90.28% 
Exercise 10,000 94.25% 
Maximal Exercise >10,000 90.45% (10,000) 
 
For the current Emax, which is 1.0 mmHg/ml, when the aortic valve shuts permanently, the 
value of FTCO lies between 90% and 100%. If the volume of blood ejected in a cardiac cycle is 
considered, then the aortic valve dynamics can be studied in terms of a ratio of blood ejected 
through the aortic valve in a cardiac cycle over the total volume of blood ejected in a cardiac cycle 
(FH). Similarly, the dynamics of the LVAD can be represented in terms of a ratio of blood ejected 















Figure 4.5: FH for different levels of activities and speeds for a patient with Emax = 1.0. 
 
 
Figure 4.6: FP for different levels of activities and speeds for a patient with Emax = 1.0. 
These ratios by themselves standing alone do not probably provide much information 
except that it might be possible to use this map as a way to tune the speed of the LVAD to adjust 
the amount of blood ejected in a cardiac cycle. The Figures 4.5 and 4.6 give an idea of the 
cooperation between the heart and the LVAD in supplying blood to the affected patient. At any 










































given activity level, as FH decreases, FP increases and when FH reaches 0%, indicating closure of 
the aortic valve, FP reaches 100% to indicate that the LVAD now fully supports the patient. For 
instance at light movement, when LVAD speed is 4,000 RPM, FH is 40.39% and FP is 59.61%. 
When the speed is 5,000 RPM, FH is 24.35% and that means FP is 75.65%. To put it in words, at a 
speed of 4,000 RPM when the patient is involved in light movement, of the total blood ejected in 
a cardiac cycle, about 40% comes out through the aortic valve, when it is open intermittently 
(AVOP = 25.68% of the cardiac cycle) and the remaining 60% comes out through the LVAD 
which runs throughout the cardiac cycle. When the speed is 5,000 RPM, the fractional value is 
lower for FH, at nearly 25%, and FP increases closer to 75% (AVOP = 21.74% of the cardiac cycle).  
4.3.2 Dynamics of LVAD Flow 
As seen in Chapter 2, the flow of blood through the LVAD is split further into two 
components, one due to the impeller of the LVAD and the other due to the contraction of the heart 
itself. In such a scenario, the effects of the heart on the pump and that of the pump itself on the 
analysis of meeting the demand for blood on activity is possible. FPH is the fraction of blood 
flowing through the LVAD due to contraction of the ventricle, and FPC is the fraction of blood 
flowing through the LVAD due to the impeller alone. By extension of the definition in 















Figure 4.7: FPC for different levels of activities and speeds for a patient with Emax = 1.0. 
The plot in Figure 4.7, shows FPC for all the activity levels. As the speed of the LVAD 
increases, FPC shows an increase irrespective of the activity level. At a speed of 2,000 RPM, FPC 
ranges between 5% - 10% depending on the activity. These values indicate that at 2,000 RPM, the 
contribution of the pump is majorly driven by the heart muscle contraction pushing blood through 
it thanthe impeller action. FPH on the other hand, at 2,000 RPM shows a more considerable 
variation from 7% at maximal exercise to 16% for resting. These fractions go further to help 
understand the way the LVAD supports the patient implanted with them. As the speed of the 
LVAD increases, the impeller slowly becomes the major contributing factor of blood for the 
amount of blood ejected during a cardiac cycle. FPH shows a new pattern, in Figure 4.8, where it 
increases with increasing speed, reaches a maximum at the speed where the aortic valve 
permanently shuts off and then decreases but does not go to 0. The meaning of that is, the actions 
of the heart are still influencing the LVAD but at the speeds where the aortic valve is closed, the 
effect of the heart starts to go down.  






















Figure 4.8: FPH for different levels of activities and speeds for a patient with Emax = 1.0. 
 
Figure 4.9: Measure of how FPH measures against FP. The percentage of flow in the LVAD due to the heart and not 
including the impeller. 









































Figure 4.10: Measure of how FPC measures against FP. The percentage of flow in the LVAD due to the impeller 
setting. 
At any given speed when the aortic valve is open, the contribution of the heart to the blood 
flow in the LVAD irrespective of the activity does seem to be the same, and drops with an increase 
in speed, but changes or drops drastically only when the aortic valve shuts down permanently. A 
similar phenomenon but one that increases with increasing speed and a rate change in the 
contribution of the impeller after the aortic valve permanently shuts is observable for the 
participation of the impeller. FPH relative to FP is shown in Figure 4.9 and FPC relative to FP is 
shown in Figure 4.10. These indicate that as far as the dynamics of the LVAD go, it also depends 
on the dynamics of the aortic valve in a sense, the aortic valve plays a direct role in the way the 
LVAD unloads the ventricle. At a speed of 5,000 RPM, the impeller is responsible for between 
62% and 65% of the blood flowing through the LVAD, 62% being the level at resting, and 65% 
being the level at maximal exercise. On the other hand, the heart muscles push through 35% to 
38% of the blood through the LVAD, with 35% being at maximal exercise and 38% at resting. At 
speeds where the aortic valve is permanently closed, the difference between each level of activity 




















for the relative contribution by the impeller shows about a 4% variation for each level of activity 
when for speed and activity, the aortic valve is closed.  
4.3.3 Mapping FH, FP with FTCO 
Having discussed the fraction of blood that is provided by the combination of both the heart 
and the LVAD, alongwith the individual paths, it might be useful to provide a map that shows the 
total fraction of blood ejected as compared to a healthy person (FTCO) with the contribution of each 
path relative to the total volume of blood removed in a cardiac cycle (FH and FP). Such a map 
would help in knowing the exact cooperative dynamics between the heart and the LVAD in 
providing a certain fraction of blood relative to a healthy patient.  
The map can also be useful in identifying the correct operating speed of the LVAD to 
provide a balance for the combined system, in that the rate of the LVAD should not burden the 
heart than what it needs to be. This condition will depend on the state of the patient, and the 
therapy, which might require the patient to be either in complete support or partial support, wherein 
the heart will still eject blood through the aortic valve. The map also could provide a basis on 
which the speed of the LVAD can be controlled, either left to be in a fixed speed or vary according 
to activity level. Such a map might be helpful in building on a robust control law has discussed by 




Figure 4.11:A map combining FH and FP that can be used to set the contribution of the LVAD against a required 
FTCO. 
The map is shown in Figure 4.11, where both FH and FPis placed on the x – axis and FTCO 
is placed on the y – axis. It is known that FH = 100 – FP, which means concentrating on either of 
FH or FP can be sufficient in satisfying both the possible uses of the map. In order to maximize 
blood supply in a cardiac cycle, FTCO should be high. As seen earlier, and shown by the map, FTCO 
greater than 90% means FH = 0% or FP = 100%. Any higher FTCO means the pump satisfies all the 
blood requirement and the exact level of FTCO is dependent on the speed of the LVAD. If FTCO and 
its level is the main requirement, then it essentially comes down to the speed of the LVAD that 
would determine the FTCO value. Yet, in the scheme of therapy, if the aortic valve has to be opened 
to a certain level, then depending on the share that the aortic valve needs to supply, FTCO value can 
be found. If FH, for instance is 70%, FP is 30%, then FTCO across the activity spectrum is about 
77%. Now, when FH is close to 30%, with FP being 70%, FTCO varies between 85% for rest to 89% 
for maximal exercise and when FH is 50%, meaning both the heart and pump are sharing equally, 
then FTCO is about 80%.  

























While it might be better to have a greater FTCO, meaning the share of the heart needs to be 
lesser than 50%, and the closer it is to 0%, the chance of maximizing the FTCO. Essentially, in a 
scenario where for a patient with a LVAD implanted, in order to meet the change in blood demand 
during exercise in relation to a healthy person, the results indicate that a normal aortic valve 
dynamics actually plays a hindering role. At the same time, at rest the patient might not be 
requiring blood to the fullest extent and that they might be able to sustain with a lower level, that 
it might be advisable to let the aortic valve be involved in the circulation. The speed of the LVAD 
might be such that, at rest it might be high enough to shut the aortic valve, meanwhile at maximal 
exercise it might not be sufficient to do the same. At rest, the aortic valve permanently shuts down 
at 5,500 RPM, whereas the valve is open when the activity rises a little higher to light movement. 
Since the LVAD alone works at rest, the blood that is supplied might be more than a light 
movement and this is because of the dynamics the aortic valve brings in.  
Whereas, if the speed of the LVAD is not fixed and can be varied according to the activity, 
then there is a greater opportunity to meet up with the demand. In other words, it might be possible 
to keep FTCO close to 100%, which is meeting all the blood requirement as a healthy patient. A 
possible scenario is that of a patient who has the speed of the LVAD set at 7,000 RPM. At rest 
FTCO would be close to 100%, when the patient decides to make a short, slow paced walk. The 
FTCO immediately at this point falls to about 90%. If the speed were to be adjusted close to 8,000 
RPM, then for this short movement, then FTCO could be maintained at 100%. Irrespective at these 
speeds the aortic valve is shut, which allows for fulfilling a FTCO of 100%. At no speed in the range 
discussed at maximal exercise, does the FTCO reach 100%. This raises the prominent point that no 
matter what, for the given heart condition, the aortic valve functions well enough to make an 
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impact on the blood supplied to the body. There is going to be a shortfall of blood at maximal 
exercise and the presence of LVAD does not provide sufficient blood.  
4.4 The impact of Contractility – How is the blood demand met for activity as compared to a 
patient with a higher contractility but not a fully healthy person 
In the previous section, the discussion was based on a patient whose Emax was 1.0 
mmHg/ml and the comparison was with a healthy person whose Emax was kept at 2.0 mmHg/ml. 
A curious question that arises at this juncture is that of patients who undergo treatment as bridge 
to recovery rather than destination therapy or bridge to transplant. Effectiveness of BTR as a 
treatment would be in achieveing an improvement in the heart condition and in extension in the 
current discussion, FTCO. An exhaustive analysis involves discussions of various levels of Emax, 
beginning at 0.5 mmHg/ml to 2.0 mmHg/ml. Normally, for Emax levels greater than 1.0, an LVAD 
treatment might not be started, whereas if in BTR any recovery would reflect in an improvement 
in contractility or Emax.  
A patient whose Emax is 0.5 mmHg/ml is implanted with an LVAD, then this Emax is 
assigned as the base value. At this base value, FTCO, FAV, FLVAD, FH and FP are taken up for 
discussion. First, these values are compared to that of the healthy person as in the previous section 
to develop a comparative study. The plot of FTCO when compared to a healthy person is expected 
to follow the pattern seen in Figure 4.2, which is shown in Figure 4.12. At the sametime, a variation 
is observed at the lower spectrum of activity, in that just before the aortic valve permanently shuts, 
FTCO reaches a minor peak, then falls a little, before it begins to constantly rise once the LVAD 
picks up all the flow after the aortic valve shuts down. FTCO hovers around 50% at all activity 
levels at a speed of 2,000 RPM, and as the speed increases, FTCO slowly increases, and as stated 
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before, for activities ranging between resting and mild exercise, it attains a peak. The peak occurs 
at 3,300 RPM for resting condition, where the FTCO is around 56.66% and subsequently drops a 
bit to 56.10% , about a 10% drop at 3,700 RPM, which is the speed at rest when the aortic valve 
permanently shuts. Eventually beyond this point, the value keeps increasing as speed increases as 
is expected from Figure 4.2.  
 
Figure 4.12: FTCO at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a 
healthy person. 
Primarily this occurrence of the peak is due to the blood ejected through the aortic valve. 
Investigating the flow of blood, a similar occurrence of peak at the speeds mentioned can be 
observed in the flow through the aortic valve, whereas the flow through the pump seems to follow 
a smoother increase with speed. Also, with changing activity, a peak can be observed at a speed 
closer to where the aortic valve permanently closes with varying peak and variations in the 
fractional values surrounding the peak. At higher activities the peak seems to be not occurring 
within the steps of speed that have been simulated. As discussed in the previous section, other than 
this occurrence of a local peak near the closure of the aortic valve, the analysis of the fractions 
























follow the results for Emax = 1.0. Essentially, given that the heart failure is more prevelant, the 
combined system does have a greater short fall in meeting the demand equivalent to a healthy 
person when the aortic valve is operational. After it’s closure, the short fall exists at higher levels 
of activity and at lower levels, especially at rest, the fractional value is lower than with Emax of 1.0, 
but the gap narrows as the speed gets higher. For instance, the FTCO is 79.71% when Emax = 0.5 at 
a speed of 6,000 RPM, where the aortic valve is permanently closed, as compared to 90.97% for 
Emax = 1.0, which also is at a speed which has shut the aortic valve.  
The influence the pump has on FTCO at a greater level of heart failure can be observed at 
rest than at maximal exercise, with the pump not helping to produce enough blood when greater 
exercise is involved. Essentially, what this shows is that the LVAD cannot provide sufficient blood 
at higher activity to make a patient be able to do such activities. The base thus far has been a 
healthy person. Yet, any improvement in contractility is useful. If for a patient with Emax of 0.5,  
the LVAD can support enough to carry out activities of a person whose Emax is 20% better, then a 
different perspective can be drawn.  
The FTCO for a patient with Emax = 0.5 as compared to a person whose Emax is 20% better 
and no LVAD implanted is shown in Figure 4.13. In comparison to Figure 4.12, it is clear that 
values of FTCO is certainly higher at every level of activity for the same speed. At a speed of 2,000 
RPM the value of FTCO for all levels of activities is around 90%, whereas it does touch 100% at 
speed levels when the aortic valve is still operational. As the speed approaches a greater value, say 
for example 6,000 RPM, the blood that is ejected at rest is close to 140% of the blood that is ejected 
for the patient with no LVAD and albeit FTCO is lower at maximal exercise in comparison to rest, 




Figure 4.13: FTCO at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a 
person with heart failure 20% better. 
 
Figure 4.14: FAV at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a 
person with heart failure 20% better. 
Figure 4.14 shows the plot of FAV as compared to the test patient for different activities to 
give an indication of how much in the total volume of blood ejected does the heart supply in 
conjunction with the LVAD. At rest the heart provides lower support than the LVAD at all speeds 
as is shown by Figure 4.15, which shows the FPV. It means that the LVAD is able to provide 












































sufficient support to meet the requirement of the patient to be able to carry out activity levels which 
the patient would not normally be able to without the support of an LVAD. This fact is further 
substantiated by Figures 4.16 and 4.17.  
 
Figure 4.15: FLVAD at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a 
person with heart failure 20% better. 
 
Figure 4.16: FH at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a person 
with heart failure 20% better. 









































Figure 4.17: FP at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a person 
with heart failure 20% better. 
If FP greater than or equal to 50% is a measure of the LVAD being able to take up the 
demands of activity related blood needs, then from Figure 4.17 at speeds between 2,000 and 4,000 
RPM, the LVAD is able to achieve this level of sharing of blood at all the levels of activity from 
rest to maximal exercise.  
 
Figure 4.18: FPH at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a 
person with heart failure 20% better. 








































Figure 4.19: FPC at different speeds and different activity levels for a patient with Emax of 0.5 as compared to a 
person with heart failure 20% better. 
If the flow of blood through the LVAD has to be further broken down as a measure of 
meeting the demands of activity and how the heart influences the flow in the LVAD and how the 
impeller takes it up, Figures 4.18 and 4.19 shows the plots of FPH and FPC. The plot of FPH shows 
a peak profile, wherein the maximum influence of the heart pushing blood into the LVAD 
occurring at rest, attaining a peak at a speed of 3,700 RPM. The maximum influence of FPH ranges 
between 20% - 34%, from maximal exercise to rest, of the blood supplied in a cardiac cycle for 
the patient as compared to the test patient with 20% better Emax and not having an LVAD. FPC on 
the other hand shows a linear variation as a function of LVAD speed for all levels of activities.  
All the analysis shown in Figures 4.13 – 4.19, indicate that a patient supported with LVAD 
is able to be supplemented with blood equivalently to a patient whose contractility of about 20% 
higher. Upon investigation at increased contractility, upto 80% higher, albeit at lower LVAD 
speeds the blood supplied does fall short across activities, at higher speeds there is observable 
matching of the demand as elucidated in Table 4.5. It has to be kept in context that, at resting for 




















a patient with Emax = 0.5, the aortic valve permanently shuts at 3,700 RPM and for maximal 
exercise it happens at 7,300 RPM.  
Table 4.5: FTCO for Emax = 0.5 compared to incremental increase in contractility with no LVAD 
Speed Resting Maximal Exercise 
20% 40% 60% 80% 20% 40% 60% 80% 
2,000 93.03 84.44 78.16 73.00 90.72 81.96 75.50 70.64 
3,000 98.23 89.16 82.53 77.08 93.34 84.33 77.68 72.68 
4,000 103.40 93.88 86.90 81.17 96.38 87.08 80.21 75.05 
5,000 121.70 110.40 102.20 95.47 99.76 90.13 83.02 77.68 
6,000 140.70 127.70 118.20 110.40 103.50 93.48 86.11 80.56 
7,000 160.30 145.50 134.60 125.80 107.80 97.41 89.73 83.95 
8,000 180.10 163.50 151.30 141.40 118.10 106.70 98.30 91.97 
9,000 200.20 181.70 168.20 157.10 129.90 117.40 108.10 101.20 
10,000 220.50 200.20 185.30 173.10 141.90 128.20 118.10 110.50 
 
A 20% increase in contractility is a scenario that actually provides the best possible option 
if the aortic valve has to be operational, and still look to achieve a complete satisfaction of the 
blood demand for all kinds of activity. FTCO in this case reaches 100, for rest at a speed of 3,300 
RPM and for maximal exercise at 5,100 RPM. Clearly in both the extremums, the aortic valve is 
operational. The example case stated here is for a patient with Emax of 0.5, and hence it is vital to 
study the effects of a 20% increase in contractility for a few more cases of Emax, which are 
summarized below.  
For Emax between 0.5 and 1.0, there are surely various ranges of speed that allows the 
different levels of activity to be supported by the LVAD equivalently to an unsupported heart 
which has a contractility of about 20% greater. The approach of understanding the demand met 
might provide a way to analyze the recovery of a heart in treatments like bridge to recovery.  
For control of the LVAD using the speed, using fixed speed, for activity changes, it has 
been seen that the blood demand might not be met. Taking for example, activity changing from 
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resting to maximal exercise in slow progression, as compared to a person whose Emax is 20% 
higher, then changing speed from 4,000 RPM to 6,000 RPM the FTCO can be kept at 100% or 
slightly above. A variable speed controller instead of fixed speed control might be the step forward 
to further the treatment of a patient with heart failure.  
4.5 Fraction of Aortic Flow and Aortic Valve Ejection Fraction 
As discussed in the previous chapter, the definition of Aortic Valve Ejection Fraction, 
AVEF, might be similar to the fraction of blood flow through the aortic valve, FAV described in 






=  (4.8) 
 AVVAVEF
LVVBE
=  (4.9) 
The denominators of the two ratios are the differentiating factor, other than that what we 





=  (4.10) 
For a patient with Emax = 0.5, Figure 4.20 shows the plot of FAV versus AVEF for the 




Figure 4.20: Plot of FAV versus of AVEF 
The plot shows an interesting observation. The variation between the activities at different 
speeds but for the same FAV shows that an approximation could be done for this particular Emax. 
Applying a polynomial fit, a linear fit is possible as defined in (4.11).  
 *HF AVEF= Γ + ϒ  (4.11) 
In the case considered, Γ = 3.9 and ϒ =  -10-21 (p = 0.05). The conditioning for this fit 
makes the fit parameters SSE = 9.39, R2 = 0.9999 and RMSE = 0.1526. A conditioned fit to account 
for robustness using LAR, centered and scaled around the mean value gives, Γ = 20.3, ϒ = 13.77, 
where FAV is normalized around the mean of 3.521 with a standard deviation of 5.19. In short, 
there is about a half factor that links FAV and AVEF, irrespective of activity levels. 
With respect to the different contractility levels, while applying the same linearization, Γ
values can be seen to hover around 0.5 till Emax = 1.25 and beyond that there is a drop in value to 
levels less than 0.5 in a non-linear manner.  























In this chapter, the sharing or cooperation of the the heart and LVAD was introduced in 
terms of the fraction of blood that each of the paths provide, with respect to the total volume of 
blood ejected in a cycle, as well as with respect to the relative volume of blood compared to a 
healthy person. These were tested to see if, at a fixed speed,the LVAD will be able to provide 
sufficient support at different levels of activity, for which the volume parameters were tested 
against the parameters of a healthy person. It is to be noted that LVAD at speeds when the aortic 
valve is operational is not able to provide the sufficient blood. Whereas when the LVAD alone is 
operational, there is a possibility of meeting the requirements as a healthy person for different 
activities. The heart could act as a limiting factor in the cooperative scheme involved in the 
combined system. Similarly when the test patient is changed to a heart failure patient whose 
contractility is slightly better, the LVAD is able to provide much better support. Finally, 
understanding the link between the fraction of the blood that flows through aortic valve with 
respect to AVEF shows a relationship that can be summarized to be used in developing a control 
mechanism for the speed of the LVAD, as well as monitor recovery of the heart in such treatments 
as bridge to recovery. 
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CHAPTER 5  
SUMMARY, CONCLUSION AND FUTURE WORK 
The dissertation seeked to tackle a day to day issue of how to monitor progress or recovery 
of patients implanted with a continuous flow left ventricular assist device. In congruence with the 
research topic, a hypothesis was set to try and solve this question. The hypothesis defined was, a 
constant monitoring of ejection fraction modified to account for the blood being ejected through 
the LVAD will ideally be a metric that allows to deduce the recovery of the patient. Further on, 
this very ejection fraction should be able to also give information about the interaction between 
the heart and the LVAD that can be used to understand the control settings and activity response 
of the implanted patient. In doing so, the dissertation did discuss a few topics in the previous 
chapters. This particular chapter would serve as a summary of all the topics discussed, provide a 
conclusion or comment on the hypothesis and finally list the possible future directions in which 
the research can be taken forward.  
5.1 Summary of Work 
The results presented in this dissertation towards the study of the hypothesis, attempts to 
provide possible engineering approaches to understanding various cardiac function parameters for 
analysis of the LVAD in a heart failure patient. Towards that goal, a combined cardiovascular – 
LVAD model that is validated to accurately represent the system was used to perform relevant 
simulations.  
The modeling and the basic physiological theory behind such a model that can be used to 
study heart failure patients are introduced in Chapter 1. An overview of the heart, cardiac cycles 
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and the 5th and 6th order nonlinear models of the cardiovascular system that focuses primarily on 
the left heart was discussed. These facilitate to develop a comprehensive simulation platform to 
study the various aspects of either the heart or the LVAD as per the patients. In this dissertation, 
the model is generic and uses a generic axial flow pump, whereas in the event of need, the model 
can be tailored to individual patients by appropriate calculations of the various model parameters.  
The first contribution of the dissertation is to identify or characterize the various blood 
flows that occur in the combined cardiovascular – LVAD system. To this effect in Chapter 2, the 
various blood flows, namely through the aortic valve, the pump and the mitral valve, basically all 
the inlets and outlets from the left ventricle were introduced. It must be noted that measuring real 
– time flow might be difficult and hence to overcome this issue, the equivalent volumes of blood 
in a cardiac cycle were then defined. The volume of blood ejected through the aortic valve, which 
typically occurs only during the time period when the aortic valve is open, the volume of blood 
ejected through the LVAD and the volume of blood that enters the left ventricle through the mitral 
valve were listed and defined. The characterization of these volumes, especially the ejection 
volumes in regards to the ventricle were studied with respect to the rotational speed of the LVAD 
and the contractility of the heart.  
The results showed that the volume of blood through the aortic valve steadily reduced with 
increasing speed of the LVAD, eventually dropping down to 0 when the aortic valve shut 
permanently. At the same time, the volume of blood through the LVAD increases as the speed of 
the LVAD does, indicating better draining capability of the pump. What was interesting in this 
approach was that the total volume of blood ejected, which is the sum of the two, showed almost 
a constant value for the speeds when the aortic valve was operational. Next, the same volumes 
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were analyzed for different contractilities. When the contractility increased, the volume of blood 
ejected through the aortic valve showed increase, whereas the volume of blood ejected through the 
LVAD showed minimal variation to a small drop across the range of contractilities considered.  
It was also reported that the volume of blood flowing through the LVAD is influenced both 
by the mechanics of the pump and the heart. These flows were further split and studied, indicating 
that even after the aortic valve is shut down permanently, the heart still pushes blood through the 
LVAD. Also studied was the volume of blood flowing through the mitral valve that flows into the 
ventricle. An analytical approach of modeling these volumes in terms of a regression model as a 
function of speed and contractility was introduced.  
The next contribution of the dissertation was to use the volumes introduced in Chapter 2  
to study the left ventricular volume curve in the presence of a continuous flow LVAD. The 
continuous unloading of blood due to the presence of the LVAD alters the shape of the LVV curve 
in such a way that, a metric used to identify heart failure, namely ejection fraction in the standard 
way might not be useful. As such the dissertation defines a new Aortic Valve Ejection Fraction 
(AVEF), which removes the contribution of the LVAD in the calculation of ejection fraction and 
represents a relative ejection fraction through the aortic valve. When the aortic valve is operational, 
the value of AVEF represents the fraction of blood that goes through the aortic valve into the aorta 
and when the valve is shut permanently the value of AVEF is 0. The variation of AVEF with 
rotational speed of the LVAD, afterload and contractility were discussed. Finally a generic map of 
the Frank – Starling Curve using the definition of AVEF was interpreted as to how the parameter 




The final contribution of the dissertation was to further investigate the sharing of blood 
through the two paths of the combined system.  The sharing of blood in terms of the cooperation 
between the heart and the LVAD was used to study the ability of the LVAD to support change in 
activity that the patient might be undergoing post – implantation. For this, the fraction of total 
volume of blood ejected in the combined system against a test case, which initially was taken to 
be a healthy person was studied for a range of speed and five cases of activities. The individual 
volumes through the aortic valve and LVAD were also defined against the test case to analyze how 
the heart and the LVAD provide at each speed and activity. The actual cooperation or sharing were 
studied by analyzing the fractions of volumes of blood through the aortic valve and the LVAD 
against the total volume of blood ejected in a cardiac cycle for the various cases. It provided a 
measure of whether the heart does more work in a cardiac cycle or the LVAD. This analysis in a 
clinical setting might be useful in understanding the amount of stress that can be put on the ailing 
heart and also to know if there is a way to provide a feedback system to adjust the speed of the 
LVAD according to the activity requirement. For this, given the fact that the LVAD does not 
provide sufficient support on changing activity, a case where the test case was changed and the 
analysis was done again, this could be the way in which one might have to look into in a clinical 
setting.  
Finally, to provide a method to link a measurable parameter to study the cooperative 





For a heart failure patient implanted with a continuous flow left ventricular assist device, 
studying the AVEF at regular intervals would provide the ability to make an inference about the 
recovery of the heart muscle. This dissertation addresses this by first characterizing the blood 
volumes involved in a cardiac cycle with an LVAD implanted and showed the feasibility of 
individualizing each of them. The ability to further define Aortic Valve Ejection Fraction, which 
represents the ejection fraction relative to the ejection that occurs through the aortic valve is due 
to the fact that such a characterization of blood volumes is possible. The research has also shown 
that AVEF, thus defined, is dependent on speed, contractility and also the afterload. AVEF also 
has the ability to provide a measure of the cooperative mechanism involved in the supply of blood 
to the circulatory system by the combined cardiovascular – LVAD system. In a clinical setting, if 
a patient is monitored for AVEF at a fixed setting in terms of speed and activity, at regular intervals 
under the same setting if the measurement of AVEF shows an improvement, then this change in 
AVEF is due to the change in contractility, which indicates improvement of the heart or recovery 
of the heart. If in any case there is a change in setting, it is possible to study the various parameters 
in detail as the dissertation as shown, it still provides the ability to conclude that any change in 
AVEF is due to a change in contractility.  
5.3 Future Work 
The obvious limitation of the dissertation is that the work is primarily based on a model 
and the results are simulated. In a clinical setting with different types of LVAD pumps available, 
it might not be the one stop solution. So the first possible future expansion would be to do bench 
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flow study of the pumps to understand the various parameters discussed. The possibility to extend 
the different pumps that could be replaced in the model with and studying AVEF for them would 
be a fundamental step in order to make AVEF clinically viable. In addition, it is important to come 
up with a validated method to measure AVEF non – invasively and frequently. Techniques such 
as echocardiography, ultrasound, photoplethysmography and pulse oximetry needs to be studied 
for the feasibility to measure AVEF.  
Given the use of AVEF to study the cooperation between the heart and the LVAD, it can 
be proposed to be utilized as a possible feedback control mechanism to adjust the speed of the 
LVAD pump as per the needs of the patient in case of any possible activity change. Any of the 
state variables discussed are difficult to measure when it comes to using the as a feedback control 
mechanism. Any feedback control mechanism should be to use a measurable parameter in real – 
time to be able to work on the control law that would be able to regulate the speed.  
One of the possibilities would be to use AVEF as that measurable parameter which would 
then be used in the control logic to act on the control law which would be able to control the speed 
of the LVAD. Given the ability to study the fractional flow of blood using AVEF, in future work 
it should be possible to develop flow characteristics for the LVAD pumps in market and establish 
a cooperative mechanism chart, that can be used to develop a control law.  
Currently there is some research towards developing a feedback control mechanism to 
control the speed of the LVAD. One approach is to develop a Frank – Starling like controller using 
Left Ventricular End Diastolic Pressure. A surrogate for that would be the Left Ventricular Volume 




The idea using AVEF would be to use AVEF as a Frank – Straling mechanism surrogate, 
to provide the reference AVEF that would need to be attained by regulating the speed. Additional 
constraints regarding on the fractional work done by the heart and the LVAD could be added in. 
The controller currently being looked at is a PID controller, and as a future extension an optimal 
control algorithm could be looked at.  
Another direction that the dissertation can be utilized in is developing an aid or tool 
utilizing the model and all the various parameters studied for the physician. An app like tool, which 
can be tailored to an individual and the type of pump implanted, the model should be able to run 
many scenarios to provide a guide to the physician without much requirement for invasive or non 







Heart Rate (HR): The number of heart beats per unit time, commonly referred to as beats 
per minute (BPM). It is calculated as shown below 
 60HR
T
=  (A.1)  
where, T is the cardiac period or the time taken for one cardiac cycle. Left Ventricular 
Pressure (LVP): It is the pressure generated in the ventricular chambers of the heart. It plays a vital 
role in understanding changes in cardiac function. The blood in the ventricle is primarily 
responsible for the generation of this pressure[151].  
Left Atrial Pressure (LAP): It is the pressure generated in the left atrium due to the buildup 
of blood in it, which is responsible for sending the blood into the left ventricle[152].  
Systole: It is defined as the period of the cardiac cycle when the heart muscles contract 
after the heart refills with blood[153].  
Diastole: It is defined as the period of the cardiac cycle when the heart refills with blood 
after being emptied during a Systole[153]. 
Arterial Pressure (AP): Without explicit specification, blood pressure generally refers to 
the pressure the blood circulation exerts on the walls of the large arteries, otherwise known as 
arterial pressure. The blood pressure consists of two components, the systolic pressure, the 
maximum pressure between two cardiac cycles and the diastolic pressure, the minimum pressure 
between two cardiac cycles. 
Aortic Pressure (AoP): The pressure at the root of the aorta is known as the aortic pressure.  
Left Ventricular Volume (LVV): The instantaneous volume of blood available in the left 
ventricle during a cardiac cycle is called the Left Ventricular Volume. 
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Isovolumic Relaxation: The ventricles relax as both the mitral and aortic valves close, 
resulting in a rapid decrease in pressure without any change in the blood volume inside the 
ventricle. Since there is no change in the blood volume, it is called isovolumic. As the blood from 
the pulmonary vein fills the left atrium, it causes a gradual increase in the left atrial pressure. 
Initially its pressure is still lower than the left ventricular pressure, and this ensures that the mitral 
valve remains closed during the entire phase. Also, the aortic pressure remains higher than the left 
ventricular pressure thus ensuring  the closure of the aortic valve.  
Filling: The left ventricular pressure keeps decreasing until it is lower than the left atrial 
pressure. The pressure difference leads to the opening of the mitral valve and the blood flows from 
the left atrium to the left ventricle, thereby filling it. This filling happens in two different phases: 
one, just when the valve opens, which is rapid and; two, a steady filling towards the end of the 
filling phase when the valve is about to close. During the phase of filling, the left ventricular 
pressure increases slowly but still is lower than the aortic pressure thereby keeping the aortic valve 
closed. 
Isovolumic Contraction: Mitral valve closes when the pressure in the left ventricle is higher 
than the left atrium. Also, the ventricular pressure at this phase is still lesser than the aortic 
pressure, thus keeping both the mitral and aortic valves closed. The left ventricular pressure rapidly 
increases due to the contraction of the ventricular muscles along with the closed aortic valve since 
the aortic pressure keeps dropping. 
Ejection: The pressure in the left ventricle continues to build up and eventually exceeds the 
aortic pressure leading to the opening of the aortic valve. Ejection of blood from the left ventricle 
into the aorta occurs during this time. The rate of ejection from the ventricle is dependent on the 
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volume of blood left in the ventricle and stops only when the pressure in the ventricle becomes 
less than that of the aorta. The mitral valve remains closed during this phase. 
End Systolic Volume (ESV): Defined as the volume of the blood inside the ventricle at the 
end of the systole. It is generally the lowest volume of blood during the cardiac cycle, thus it can 
be used clinically to measure the ability of the heart to pump blood.  
End Diastolic Volume (EDV): Defined as the volume of blood inside the ventricle at the 
end of the diastole. 
Stroke Volume (SV): Defined as the volume of blood that is pumped by the ventricle in 
one beat. It can be calculated as the difference between the end – diastolic volume of blood and 
the end – systolic volume.  
 SV EDV ESV= −  (A.2)  
Cardiac Output (CO): Defined as the volume of blood ejected by the ventricle every 
minute. In other words, it is stroke volume times the number of heartbeats in a minute.   













Blood flow (Q) depends on two factors, the pressure difference ( P∆ ) between the ends of 
a blood vessel and the resistance that the vessel presents to the flow of blood  






=  (B.1)  
Close inspection shows that this expression is similar to Ohm’s law, which describes the 




=  (B.2)  
Expressions (from appendix) and (1.2) draw a close comparison that can be seen between 
the respective terminologies. The pressure – volume relationship is called vessel compliance, 
which acts as a measure of the ability of a blood vessel to expand and contract in response to 
changes in pressure. The effect of compliance for large arteries and veins are essential in modeling 
whereas that for smaller vessels can be neglected. Defining it, compliance is the ratio of the change 







 (B.3)  
It must be noted in the human cardiovascular system all of the volumes, pressures, and 
hence flow and compliance are all time – varyingand not a constant. Now dividing the numerator 











 (B.4)  
replacing dV
dt
 which is the flow rate ( )Q t , we have (B.4) rearranged as, 
 ( ) dPQ t C
dt
=  (B.5)  
C is the capacitance that can be used to model the compliance of a vessel, which describes 








 (B.6)  
Therefore, the current and voltage applied on a capacitor is related as shown in (B.7) 




=  (B.7)  
The relationship between the inductance of an inductor, the current passing through it and 
the voltage is given by  
 ( )( )ind
di tv t L
dt
=  (B.8)  
Similarly, blood inherently has an inertance and this can be modeled using the concept of 
inductance in electric circuits. Blood inertance ( )vesL  relates the pressure drop with the rate of 
change of flow and the pressure as  
 ( )( ) ves
dQ tP t L
dt




DIFFERENTIAL EQUATION MODEL OF VENTRICLE USING 
ELECTRICAL ANALOGUE  
139 
 
In Figure 1.4, applying circuit laws, a system of time-varying differential equations can be 
derived[41, 42, 44, 60]. These are represented as a state space model shown in the following 
equations (C.1) – (C.5) with the state variables of the system listed in Table 1.5. 
 1 2( ) ( ) ( )x A t x A t r x= +  (C.1) 
Where, ( )x t is the state vector representing the hemodynamic variables as described in 
Table 1, 1 2( ) and ( )A t A t are 5×5 and 5×2 time-varying matrices, respectively, ( )r x is a 2×1 vector 
mimicking the nonlinear behavior of the two valves (or diodes).  
 1( )
( ) 0 0 0 0
( )
1 10 0 0
1 1 10 0
10 0 0 0
1 10 0
S R S R
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 (C.5)  
The non – linearity caused by the diodes is represented by the ramp function ( )r ξ  which 
















COMBINED CARDIOVASCULAR – LVAD MODEL  
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The pressure difference produced by the impeller of the LVAD pump can be represented 
as the sum of the pressure gradients in the inlet cannula, IH  , the pump head PH  and the pressure 
gradient in the outlet cannula, OH , as shown, 
 ( ) ( ) I P OLVP t AoP t H H H− = + +  (D.1) 
The terms on the right-hand side in (D.1)are defined in [58, 59, 73]as. 
 ( )( ) PI i P i
dQ tH R Q t L
dt
= +  (D.2)  
 2( )( ) ( )PP P P P
dQ tH R Q t L t
dt
βω= + −  (D.3)  
 ( )( ) PO O P O
dQ tH R Q t L
dt
= +  (D.4)  
The parameter β  is a pump –dependent constant and ( )tω  is the pump rotational speed. 
The parameters in (D.1) – (D.4) are all defined in Table 1.8. 
The resistance to the flow during suction, usually needs to be added to (D.3) as in [41, 42, 
44, 58-60]. In the scope of the current research, we do not consider this due to the pump power 
levels,andsubsequently, the speed is kept at a level much lower than the onset of suction.  
Using (D.2) – (D.4) and simplifying (D.1) yields, 
 * * 2( )( ) ( ) ( ) ( )PP
dQ tLVP t AoP t R Q t L t
dt
βω− = + −  (D.5)  
Where,  




 * i P OL L L L= + +  (D.7)  
The differential equations and hence the state representation will now have to be modified 
in such a way that it includes the pump flow. In (5.5) replacing the terms with the corresponding 




6 1 4 6* * * *
1 1( ) ( ) ( ) ( ) ( )Rx t x t x t x t u t
L L L L
β
= − − +  (D.8)  
Here 2( )u t ω=  is used to denote the control variable in the model.  
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Fit Parameters and Goodness of Fit for Equation (2.18) ˆAVV : 





































ω  (2000,9000)  (2000,7900)  (2000,6600)  (2000,4300)  
µ  5500 4950 4300 3150 
σ  2064 1746 1371 707.1 
SSE 1.21 9.48e-4 1.95e-4 1.54e-4 
2R  1.00 1.00 1.00 1.00 
Adjusted 2R  0.99 1.00 1.00 1.00 
RMSE 0.13 0.004 0.002 0.003 
Robust 
Algorithm LAR Bisquare Bisquare LAR 
 
Fit Parameters and Goodness of Fit for Equation Equation (2.17) P̂VV : 





































ω  (2000,9000)  (2000,7900)  (2000,6600)  (2000,4300)  
µ  5500 4950 4300 3150 
σ  2064 1746 1371 707.1 
SSE 0.003 3.42e-4 2.66e-4 4.98e-5 
2R  1.000 1.000 1.000 1.000 
Adjusted 2R  1.000 1.000 1.000 1.000 
RMSE 0.007 0.003 0.003 0.002 
Robust 






Fit Parameters and Goodness of Fit for Equation Equation (2.15) P̂HV : 





































ω  (2000,9000) (2000,7900)  (2000,6600)  (2000,4300)  
µ  5500 4950 4300 3150 
σ  2064 1746 1371 707.1 
SSE 0.030 0.029 0.007 1.39e-4 
2R  1.000 1.000 1.000 1.000 
Adjusted 2R  1.000 1.000 1.000 1.000 
RMSE 0.021 0.023 0.013 0.003 
Robust 
Algorithm LAR Bisquare Bisquare LAR 
 
Fit Parameters and Goodness of Fit for Equation Equation (2.16) P̂CV : 





































ω  (2,000,9,000)  (2,000,7,900)  (2,000,6,600)  (2,000,4,300)  
µ  5,500 4,950 4,300 3,150 
σ  2,064 1,746 1,371 707.1 
SSE 0.119 0.036 0.011 2.03e-4 
2R  1.000 1.000 1.000 1.000 
Adjusted 2R  1.000 1.000 1.000 1.000 
RMSE 0.042 0.025 0.016 0.003 
Robust 





Fit Parameters and Goodness of Fit for Equation Equation (2.19): 
Volume ˆAVV  P̂VV  P̂HV  P̂CV  
































SSE 4.279 0.254 0.656 1.484 
2R  0.999 0.998 0.998 0.999 
Adjusted 2R  0.999 0.998 0.998 0.999 
RMSE 0.164 0.040 0.064 0.097 
Robust 
Algorithm 
Bisquare None Bisquare None 
 
Fit Parameters and Goodness of Fit for Equation (2.21)  
Parameter Value Range 
c 28.79 (28.76, 28.82) 
1a  -10.97 (-11.02, -10.93) 
2a  -0.07355 (-0.09311, -0.05398) 
3a  0.09705 (0.07472, 0.1194) 
1b  9.428 (9.38, 9.476) 
2b  -2.799 (-2.819, -2.78) 
3b  0.6582 (0.6356, 0.6807) 
1c  -0.08298 (-0.1005, -0.06549) 
2c  -0.07851 (-0.09809, -0.05893) 
3c  0.1981 (0.1785, 0.2178) 
SSE 76.4507  
2R  0.9996  
Adjusted 2R  0.9996  
RMSE 0.2797  






Fit Parameters and Goodness of Fit for Equation (2.22)  
Parameter Value Range 
c 33.59 (33.58,33.61) 
1a  12.87 (12.84, 12.89) 
2a  0.265 (0.2546,0.2755) 
3a  -0.09967 (-0.1116, -0.08776) 
1b  -0.588 (-0.6137, -0.5623) 
2b  0.279 (0.2685, 0.2894) 
3b  -0.08274 (-0.09478, -0.07071) 
1c  -0.1792 (-0.1886, -0.1699) 
2c  0.0657 (0.05526, 0.07614) 
3c  -0.03305 (-0.04352, -0.02258) 
SSE 21.7482  
2R  0.9999  
Adjusted 2R  0.9999  
RMSE 0.1492  
DFE 977  
 
Fit Parameters and Goodness of Fit for Equation (3.5)  
Parameter Value Range 
c 26.14 (26.11, 26.17) 
1a  -8.307 (-8.347, -8.268) 
2a  -0.4117 (-0.4279, -0.3954) 
3a  0.004445 (-0.01411, 0.023) 
1b  10.28 (10.24, 10.32) 
2b  -2.178 (-2.194, -2.162) 
3b  0.3938 (0.3751, 0.4125) 
1c  -0.1518 (-0.1663, -0.1373) 
2c  0.01586 (-0.0004121, 0.03213) 
3c  0.1349 (0.1186, 0.1512) 
SSE 52.7896  
2R  0.9997  
Adjusted 2R  0.9997  
RMSE 0.2324  
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